<html lang="en" class="pb-page js" data-request-id="94d691a370eaf256-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d691a370eaf256-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/rvaS2R3fHM80-gxdfHGxZROTdp9-V3U42wTsVNnntBjE3iHLyao_Ch_cxNf6ZflHpFZ_1JIuAWSIQX_MswxtPA=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d691a370eaf256-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.44635360593385043"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Nephrology|Endocrinology|Cardiology">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Diabetes|Chronic Kidney Disease|Coronary Disease/Myocardial Infarction"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2107519","title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","category":"Research","type":"Original Article","topics":"Diabetes|Chronic Kidney Disease|Coronary Disease/Myocardial Infarction","specialties":"Nephrology|Endocrinology|Cardiology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-08-05T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Nephrology|Endocrinology|Cardiology\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Diabetes|Chronic Kidney Disease|Coronary Disease/Myocardial Infarction\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2107519","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Quick Take","title":"Tirzepatide versus Semaglutide for Type 2 Diabetes","doi":"10.1056/NEJMdo006111","issueDate":"2021-08-05T00:00Z","age":"6Months-1990","isFree":"n","topics":"Diabetes|Chronic Kidney Disease|Coronary Disease/Myocardial Infarction","viewType":"Full","specialties":"Nephrology|Endocrinology|Cardiology"},{"type":"Research Summary","title":"Tirzepatide vs. Semaglutide Once Weekly in Patients with Type 2 Diabetes","doi":"10.1056/NEJMdo006114","issueDate":"2021-08-05T00:00Z","age":"6Months-1990","isFree":"n","topics":"Diabetes|Chronic Kidney Disease|Coronary Disease/Myocardial Infarction","viewType":"Full","specialties":"Nephrology|Endocrinology|Cardiology"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d691a370eaf256-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes"><meta name="dc.Creator" content="Juan P. FrÃ­as"><meta name="dc.Creator" content="Melanie J. Davies"><meta name="dc.Creator" content="Julio Rosenstock"><meta name="dc.Creator" content="Federico C. PÃ©rez Manghi"><meta name="dc.Creator" content="Laura FernÃ¡ndez LandÃ³"><meta name="dc.Creator" content="Brandon K. Bergman"><meta name="dc.Creator" content="Bing Liu"><meta name="dc.Creator" content="Xuewei Cui"><meta name="dc.Creator" content="Katelyn Brown"><meta name="dc.Description" content="Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy ..."><meta name="Description" content="Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy ..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-08-05"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2107519"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202108053850607"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2109957"><meta name="dc.Relation" content="YXQYoa2107519"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright Â© 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2107519">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2107519">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2107519">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM">
        <meta property="og:title" content="Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2107519">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/3224f90f-0e67-4064-b4c3-5a2a1ba8a7b4/nejmoa2107519_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/3224f90f-0e67-4064-b4c3-5a2a1ba8a7b4/nejmoa2107519_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1 (GLP-1) receptor agonist that is under development for the treatment of
type 2 diabetes. The efficacy ...">
        <meta name="twitter:description" content="Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1 (GLP-1) receptor agonist that is under development for the treatment of
type 2 diabetes. The efficacy ...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2107519">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2107519">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2107519;issue:issue:doi\:10.1056/nejm_2021.385.issue-6;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2107519" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2107519" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2107519" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2107519" class="inputDoi"><input type="hidden" value="J.P. FrÃ­as and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;385:503-515" class="inputCitation"><input type="hidden" value="06-25-2021" class="inputEPubDate"><input type="hidden" value="August 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d691a370eaf256-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Juan P.</span> <span property="familyName">FrÃ­as</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9486-1255" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9486-1255</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Melanie J.</span> <span property="familyName">Davies</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Julio</span> <span property="familyName">Rosenstock</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Federico C.</span> <span property="familyName">PÃ©rez Manghi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Laura</span> <span property="familyName">FernÃ¡ndez LandÃ³</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Brandon K.</span> <span property="familyName">Bergman</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bing</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Xuewei</span> <span property="familyName">Cui</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Katelyn</span> <span property="familyName">Brown</span>, <span property="honorificSuffix">Pharm.D.</span></span>, for <span property="author" typeof="Person" role="listitem">the SURPASS-2 Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">June 25, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">385</span></span>:<span property="pageStart">503</span>-<span property="pageEnd">515</span></div><div class="doi">DOI: 10.1056/NEJMoa2107519</div><div class="core-enumeration"><a href="/toc/nejm/385/6"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">385</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">6</span></span></a></div><div><a href="#tab-information">Copyright Â© 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJuan%2BP.%2BFr%25C3%25ADas%252C%2BMelanie%2BJ.%2BDavies%252C%2BJulio%2BRosenstock%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D6%26contentID%3D10.1056%252FNEJMoa2107519%26title%3DTirzepatide%2Bversus%2BSemaglutide%2BOnce%2BWeekly%2Bin%2BPatients%2Bwith%2BType%2B2%2BDiabetes%26publicationDate%3D08%252F05%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2107519" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJuan%2BP.%2BFr%25C3%25ADas%252C%2BMelanie%2BJ.%2BDavies%252C%2BJulio%2BRosenstock%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D6%26contentID%3D10.1056%252FNEJMoa2107519%26title%3DTirzepatide%2Bversus%2BSemaglutide%2BOnce%2BWeekly%2Bin%2BPatients%2Bwith%2BType%2B2%2BDiabetes%26publicationDate%3D08%252F05%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/fcd52fa4-6458-4a05-8d1f-5bcaab4cb89a/nejmoa2107519.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2107519.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2107519" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2107519" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2107519.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph"><a id="exam-tint-one-c"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-c">Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes.</span> The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f0.jpg"><img src="/cms/10.1056/NEJMoa2107519/asset/3224f90f-0e67-4064-b4c3-5a2a1ba8a7b4/assets/images/large/nejmoa2107519_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">The estimated mean change from baseline in the glycated hemoglobin level was â2.01 percentage points, â2.24 percentage points, and â2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and â1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were â0.15 percentage points (95% confidence interval [CI], â0.28 to â0.03; P=0.02), â0.39 percentage points (95% CI, â0.51 to â0.26; P&lt;0.001), and â0.45 percentage points (95% CI, â0.57 to â0.32; P&lt;0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, â1.9 kg, â3.6 kg, and â5.5 kg, respectively; P&lt;0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, &lt;54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03987919" target="_blank">NCT03987919</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006111/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/f8dd3e39-f989-409e-956d-38e486770c47/media/NEJMdo006111_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006111/full/" class="ng-do-media_item-title-link">Tirzepatide versus Semaglutide for Type 2 Diabetes</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 7s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph"><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-c">Glucagon-like peptide-1 (GLP-1) receptor agonists are an effective treatment option for patients with type 2 diabetes.</span> These agents act by stimulating insulin secretion in hyperglycemic states, suppressing glucagon secretion in hyperglycemic or euglycemic states, delaying gastric emptying, decreasing appetite, and reducing body weight.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3" id="body-ref-r3" href-manipulated="true">1-3</a></sup></div><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-d">Glucose-dependent insulinotropic polypeptide, the main incretin hormone in healthy persons, is insulinotropic; however, unlike GLP-1, it is glucagonotropic in a glucose-dependent manner. Under hyperglycemic conditions, glucose-dependent insulinotropic polypeptide stimulates the release of insulin, thereby lowering glucagon levels, and under euglycemic or hypoglycemic conditions, glucagon levels are increased.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4" href-manipulated="true" aria-label="Reference 4">4</a></sup> Glucose-dependent insulinotropic polypeptide receptors are abundant in adipose tissue,<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5" href-manipulated="true" aria-label="Reference 5">5</a></sup> and glucose-dependent insulinotropic polypeptide enhances both the postprandial lipid-buffering capacity of white adipose tissue and the sensitivity of adipose tissue to insulin, which may prevent ectopic fat deposition.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6-1" href-manipulated="true" aria-label="Reference 6">6</a></sup> The glucose-dependent insulinotropic polypeptide component of dual glucose-dependent insulinotropic polypeptideâGLP-1 agonism is hypothesized to act centrally to potentiate a GLP-1âinduced reduction in food intake.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7 r8" id="body-ref-r8" href-manipulated="true">6-8</a></sup> In patients with type 2 diabetes, a single molecule combining the glucose-dependent insulinotropic polypeptide receptor and GLP-1 receptor agonism may have a greater effect on glucose levels and weight control than selective GLP-1 receptor agonists.</span></div><div role="paragraph">Tirzepatide is a dual glucose-dependent insulinotropic polypeptideâGLP-1 receptor agonist. Its structure is primarily based on the glucose-dependent insulinotropic polypeptide amino acid sequence and includes a C20 fatty diacid moiety.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-2" href-manipulated="true" aria-label="Reference 7">7</a></sup> Its half-life of approximately 5 days allows once-weekly subcutaneous administration.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-3" href-manipulated="true" aria-label="Reference 7">7</a></sup> A phase 2b trial involving patients with type 2 diabetes showed that those who received tirzepatide had dose-dependent reductions in the glycated hemoglobin level and weight at 26 weeks.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-1" href-manipulated="true" aria-label="Reference 9">9</a></sup></div><div role="paragraph">Once-weekly injectable semaglutide, a selective GLP-1 receptor agonist, is approved for the treatment of type 2 diabetes at doses up to 1 mg. In trials involving patients who received semaglutide, the mean reductions in the glycated hemoglobin level have been reported to be as high as 1.8 percentage points and the mean reductions in body weight have been reported to be as high as 6.5 kg.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11 r12 r13 r14 r15 r16 r17 r18 r19" id="body-ref-r19-1" href-manipulated="true">10-19</a></sup></div><div role="paragraph">We conducted the SURPASS-2 trial (A Study of Tirzepatide [LY3298176] versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants with Type 2 Diabetes) to compare the efficacy and safety of tirzepatide at doses of 5 mg, 10 mg, and 15 mg with those of semaglutide at a dose of 1 mg in patients with type 2 diabetes that had been inadequately controlled with metformin monotherapy.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">This 40-week, open-label, parallel-group, randomized, active-controlled, phase 3 trial was conducted in 128 sites in the United States, Argentina, Australia, Brazil, Canada, Israel, Mexico, and the United Kingdom (Table S1 in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org). The <a href="#ap1">protocol</a>, which is available at NEJM.org, was approved by local institutional review boards, and the trial was conducted in accordance with the principles of the Declaration of Helsinki and in accordance with the Good Clinical Practice guidelines of the International Council for Harmonisation. All the patients provided written informed consent. The statistical analysis plan is available with the protocol at NEJM.org.</div><div role="paragraph">Three authors employed by the sponsor contributed to the trial design, and two authors employed by the sponsor were responsible for the statistical analyses. The four academic authors and the last author (who was employed by the sponsor) provided medical oversight during the trial. All the authors participated in interpretation of the data and critical review of the manuscript. The investigators were responsible for data collection, and the sponsor undertook site monitoring, data collation, and analysis. The investigators worked under confidentiality agreements with the sponsor, and all the authors had full access to the trial data, drafted the manuscript (with assistance from a medical writer paid by the sponsor), approved the submission of the manuscript for publication, and vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph">Key inclusion criteria for this trial were an age of 18 years or older and type 2 diabetes that was inadequately controlled with metformin at a dose of at least 1500 mg per day. Eligible patients had a glycated hemoglobin level of 7.0 to 10.5% and a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 25, and they had had stable weight (Â±5%) during the previous 3 months. Key exclusion criteria were type 1 diabetes; an estimated glomerular filtration rate below 45 ml per minute per 1.73 m<sup>2</sup>; a history of pancreatitis; and a history of any of the following: nonproliferative diabetic retinopathy that warranted urgent treatment, proliferative diabetic retinopathy, or diabetic maculopathy. A full list of eligibility criteria is provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-3"><h3>Procedures</h3><div role="paragraph">The patients were randomly assigned in a 1:1:1:1 ratio to receive a once-weekly subcutaneous injection of either tirzepatide (at a dose of 5 mg, 10 mg, or 15 mg; the doses were double-blinded) or semaglutide (1 mg) for a 40-week treatment period, followed by a 4-week safety follow-up period (Fig. S1). The patients were stratified at randomization according to country and baseline glycated hemoglobin level (â¤8.5% or &gt;8.5% [â¤69 or &gt;69 mmol per mol]).</div><div role="paragraph">Tirzepatide was initiated at a dose of 2.5 mg once weekly, and the doses were increased by 2.5 mg every 4 weeks until the randomly assigned dose was reached. The final dose was then maintained for the duration of the trial. Semaglutide was initiated at a dose of 0.25 mg once weekly, and the dose was doubled every 4 weeks until 1 mg was reached. The final dose was then maintained for the duration of the trial.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup> Dose de-escalation was not allowed. The initiation of new antihyperglycemic medications was allowed according to specific criteria that are described in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph">The primary end point was the change in the glycated hemoglobin level from baseline to week 40. The key secondary end points (in a graphical testing scheme, described in the Statistical Analyses Methods section in the <a href="#ap2">Supplementary Appendix</a>, Figs. S2 through S6, and Table S2) were the change in body weight from baseline to week 40 and the attainment of glycated hemoglobin level targets of less than 7.0% and less than 5.7%. Other end points were attainment of a glycated hemoglobin level of 6.5% or less and weight loss of at least 5%, 10%, or 15%; the mean change from baseline in the fasting serum glucose level and in the daily, patient-measured, mean seven-point blood glucose profiles (i.e., the mean of seven measurements); BMI and waist circumference; lipid levels; the results of an updated homeostasis model assessmentâinsulin resistance (HOMA2-IR); and the fasting glucagon level adjusted for the fasting serum glucose level. A composite end point of a glycated hemoglobin level of 6.5% or less with at least 10% weight loss and without clinically significant hypoglycemia (blood glucose level, &lt;54 mg per deciliter [&lt;3.0 mmol per liter]) or severe hypoglycemia events was also assessed.</div><div role="paragraph">The safety end points were adverse events and discontinuation of tirzepatide or semaglutide because of adverse events. Other safety end points were adjudicated pancreatic adverse events; the serum calcitonin level; the incidence of hypersensitivity reactions; the mean changes from baseline in the pulse rate and the systolic and diastolic blood pressure; the occurrence of hypoglycemia events; and the incidence of initiation of rescue antihyperglycemic therapy.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">The trial was designed to provide at least 90% power to show noninferiority of tirzepatide at a dose of 10 mg or 15 mg as compared with semaglutide at a dose of 1 mg with respect to the change from baseline in the glycated hemoglobin level at 40 weeks, with a margin of 0.3%, a standard deviation of 1.1%, and a two-sided alpha value of 0.025, assuming no difference between the treatments. We estimated that a sample size of 1872 patients would give the trial this power to show noninferiority, assuming a dropout rate of 28%.</div><div role="paragraph">Two âestimandsâ (i.e., precisely defined estimated measures of treatment effect), which were used to assess treatment efficacy from different perspectives, accounted for intercurrent events differently. First, the treatment-regimen estimand was the treatment effect between tirzepatide and semaglutide, including the effect of any additional antihyperglycemic medication for all patients who underwent randomization, regardless of premature discontinuation of tirzepatide or semaglutide and use of rescue medication. Second, the efficacy estimand was the treatment effect among all patients who underwent randomization, had all the patients continued to receive tirzepatide or semaglutide without rescue medication. All the patients who underwent randomization and received at least one dose of tirzepatide or semaglutide (the modified intention-to-treat population) were included in the analyses to assess both estimands. Patients who discontinued tirzepatide or semaglutide because of inadvertent enrollment were excluded from efficacy analyses. Details on estimands and analysis methods are provided in the <a href="#ap2">Supplementary Appendix</a>. All the reported results are for the treatment-regimen estimand, unless stated otherwise.</div><div role="paragraph">The type I error rate was strongly controlled within each estimand independently for evaluation of the primary and key secondary end points with a graphical approach. Safety analyses were performed in the modified intention-to-treat population with all the data from the start of treatment to the end of the safety follow-up. For other outcomes that were not covered in the testing strategy, the results are reported as point estimates and 95% confidence intervals when applicable; the widths of the confidence intervals have not been adjusted for multiplicity, so the intervals should not be used to infer definitive treatment effects.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Trial Patients</h3><div role="paragraph">The trial was conducted between July 30, 2019, and February 15, 2021. In all, 2526 patients were assessed for trial eligibility; 1879 patients underwent randomization, and 1878 patients received at least one dose of tirzepatide or semaglutide (Fig. S7).</div><div role="paragraph">The demographic and clinical characteristics were similar across the groups (<a href="#t1">Table 1</a> and Table S4). The overall mean duration of diabetes was 8.6 years, the mean glycated hemoglobin level was 8.28%, and the mean body weight was 93.7 kg. In all the treatment groups, the most common reasons for premature discontinuation of tirzepatide or semaglutide were adverse events (mainly gastrointestinal events) (<a href="#t2">Table 2</a> and Table S3).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2107519_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2107519_t1.jpg"><img src="/cms/10.1056/NEJMoa2107519/asset/13814f9b-f130-4659-a098-2f008274bdd8/assets/images/large/nejmoa2107519_t1.jpg" height="2628" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>Tirzepatide</span></th><th class="txxx-borders">Semaglutide</th><th class="txxr-borders">Total<br>(N=1878)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">5 mg<br>(N=470)</th><th class="xxxx-borders">10 mg<br>(N=469)</th><th class="xxxx-borders">15 mg<br>(N=470)</th><th class="xxxx-borders">1 mg<br>(N=469)</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Age â yr</td><td class="xxxx-borders shading">56.3Â±10.0</td><td class="xxxx-borders shading">57.2Â±10.5</td><td class="xxxx-borders shading">55.9Â±10.4</td><td class="xxxx-borders shading">56.9Â±10.8</td><td class="xxxr-borders shading">56.6Â±10.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Female sex â no. (%)</td><td class="xxxx-borders">265 (56.4)</td><td class="xxxx-borders">231 (49.3)</td><td class="xxxx-borders">256 (54.5)</td><td class="xxxx-borders">244 (52.0)</td><td class="xxxr-borders">996 (53.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Race or ethnic group â no. (%)<a href="#t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">American Indian or Alaska Native</td><td class="xxxx-borders">53 (11.3)</td><td class="xxxx-borders">53 (11.3)</td><td class="xxxx-borders">57 (12.1)</td><td class="xxxx-borders">45 (9.6)</td><td class="xxxr-borders">208 (11.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">6 (1.3)</td><td class="xxxx-borders shading">11 (2.3)</td><td class="xxxx-borders shading">5 (1.1)</td><td class="xxxx-borders shading">3 (0.6)</td><td class="xxxr-borders shading">25 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Black</td><td class="xxxx-borders">28 (6.0)</td><td class="xxxx-borders">21 (4.5)</td><td class="xxxx-borders">15 (3.2)</td><td class="xxxx-borders">15 (3.2)</td><td class="xxxr-borders">79 (4.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">382 (81.3)</td><td class="xxxx-borders shading">376 (80.2)</td><td class="xxxx-borders shading">392 (83.4)</td><td class="xxxx-borders shading">401 (85.5)</td><td class="xxxr-borders shading">1551 (82.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Hispanic</td><td class="xxxx-borders">325 (69.1)</td><td class="xxxx-borders">322 (68.7)</td><td class="xxxx-borders">334 (71.1)</td><td class="xxxx-borders">336 (71.6)</td><td class="xxxr-borders">1317 (70.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Non-Hispanic</td><td class="xxxx-borders shading">145 (30.9)</td><td class="xxxx-borders shading">147 (31.3)</td><td class="xxxx-borders shading">136 (28.9)</td><td class="xxxx-borders shading">133 (28.4)</td><td class="xxxr-borders shading">561 (29.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Glycated hemoglobin level</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Glycated hemoglobin level â %</td><td class="xxxx-borders shading">8.32Â±1.08</td><td class="xxxx-borders shading">8.30Â±1.02</td><td class="xxxx-borders shading">8.26Â±1.00</td><td class="xxxx-borders shading">8.25Â±1.01</td><td class="xxxr-borders shading">8.28Â±1.03</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">â¤8.5% â no. (%)</td><td class="xxxx-borders">293 (62.3)</td><td class="xxxx-borders">294 (62.7)</td><td class="xxxx-borders">303 (64.5)</td><td class="xxxx-borders">302 (64.4)</td><td class="xxxr-borders">1192 (63.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">&gt;8.5% â no. (%)</td><td class="xxxx-borders shading">177 (37.7)</td><td class="xxxx-borders shading">175 (37.3)</td><td class="xxxx-borders shading">167 (35.5)</td><td class="xxxx-borders shading">167 (35.6)</td><td class="xxxr-borders shading">686 (36.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Glycated hemoglobin level â mmol/mol</td><td class="xxxx-borders">67.46Â±11.84</td><td class="xxxx-borders">67.20Â±11.20</td><td class="xxxx-borders">66.78Â±10.97</td><td class="xxxx-borders">66.69Â±10.99</td><td class="xxxr-borders">67.03Â±11.25</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Fasting serum glucose level</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">In mg/dl</td><td class="xxxx-borders">173.8Â±51.87</td><td class="xxxx-borders">174.2Â±49.79</td><td class="xxxx-borders">172.4Â±54.37</td><td class="xxxx-borders">171.4Â±49.77</td><td class="xxxr-borders">172.9Â±51.46</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">In mmol/liter</td><td class="xxxx-borders shading">9.65Â±2.88</td><td class="xxxx-borders shading">9.67Â±2.76</td><td class="xxxx-borders shading">9.57Â±3.02</td><td class="xxxx-borders shading">9.51Â±2.76</td><td class="xxxr-borders shading">9.60Â±2.86</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Duration of diabetes â yr</td><td class="xxxx-borders">9.1Â±7.16</td><td class="xxxx-borders">8.4Â±5.90</td><td class="xxxx-borders">8.7Â±6.85</td><td class="xxxx-borders">8.3Â±5.80</td><td class="xxxr-borders">8.6Â±6.46</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">BMI<a href="#t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">33.8Â±6.85</td><td class="xxxx-borders shading">34.3Â±6.60</td><td class="xxxx-borders shading">34.5Â±7.11</td><td class="xxxx-borders shading">34.2Â±7.15</td><td class="xxxr-borders shading">34.2Â±6.93</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Weight â kg</td><td class="xxxx-borders">92.5Â±21.76</td><td class="xxxx-borders">94.8Â±22.71</td><td class="xxxx-borders">93.8Â±21.83</td><td class="xxxx-borders">93.7Â±21.12</td><td class="xxxr-borders">93.7Â±21.86</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Waist circumference â cm</td><td class="xxxx-borders shading">108.06Â±14.81</td><td class="xxxx-borders shading">110.55Â±16.05</td><td class="xxxx-borders shading">109.55Â±15.60</td><td class="xxxx-borders shading">109.04Â±14.90</td><td class="xxxr-borders shading">109.30Â±15.36</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Estimated GFR<a href="#t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Mean value â ml/min/1.73 m<sup>2</sup></td><td class="xxxx-borders shading">96.6Â±17.51</td><td class="xxxx-borders shading">95.5Â±16.62</td><td class="xxxx-borders shading">96.3Â±16.92</td><td class="xxxx-borders shading">95.6Â±17.25</td><td class="xxxr-borders shading">96.0Â±17.07</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Value &lt;60 ml/min/1.73 m<sup>2</sup> â no. (%)</td><td class="xxxx-borders">19 (4.0)</td><td class="xxxx-borders">15 (3.2)</td><td class="xxxx-borders">11 (2.3)</td><td class="xxxx-borders">19 (4.1)</td><td class="xxxr-borders">64 (3.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Value â¥60 ml/min/1.73 m<sup>2</sup> â no. (%)</td><td class="xxxx-borders shading">451 (96.0)</td><td class="xxxx-borders shading">454 (96.8)</td><td class="xxxx-borders shading">459 (97.7)</td><td class="xxxx-borders shading">450 (95.9)</td><td class="xxxr-borders shading">1814 (96.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Urinary albumin-to-creatinine ratio â no. (%)<a href="#t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">&lt;30</td><td class="xxxx-borders shading">340 (72.3)</td><td class="xxxx-borders shading">353 (75.3)</td><td class="xxxx-borders shading">357 (76.0)</td><td class="xxxx-borders shading">364 (77.6)</td><td class="xxxr-borders shading">1414 (75.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">30 to â¤300</td><td class="xxxx-borders">111 (23.6)</td><td class="xxxx-borders">87 (18.6)</td><td class="xxxx-borders">85 (18.1)</td><td class="xxxx-borders">90 (19.2)</td><td class="xxxr-borders">373 (19.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">&gt;300</td><td class="xxxx-borders shading">18 (3.8)</td><td class="xxxx-borders shading">29 (6.2)</td><td class="xxxx-borders shading">27 (5.7)</td><td class="xxxx-borders shading">15 (3.2)</td><td class="xxxr-borders shading">89 (4.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Use of metformin â no. (%)</td><td class="xxxx-borders">470 (100.0)</td><td class="xxxx-borders">469 (100.0)</td><td class="xxxx-borders">470 (100.0)</td><td class="xxxx-borders">469 (100.0)</td><td class="xxxr-borders">1878 (100.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Blood pressure â mm Hg</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Systolic</td><td class="xxxx-borders">130.53Â±14.11</td><td class="xxxx-borders">131.47Â±13.77</td><td class="xxxx-borders">130.45Â±14.32</td><td class="xxxx-borders">129.96Â±12.99</td><td class="xxxr-borders">130.60Â±13.81</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Diastolic</td><td class="xxxx-borders shading">78.61Â±8.89</td><td class="xxxx-borders shading">80.03Â±9.59</td><td class="xxxx-borders shading">78.97Â±8.97</td><td class="xxxx-borders shading">79.33Â±8.61</td><td class="xxxr-borders shading">79.23Â±9.03</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging03" data-xml-align="left">Pulse rate â bpm</td><td class="xbxx-borders">74.88Â±9.37</td><td class="xbxx-borders">74.55Â±10.75</td><td class="xbxx-borders">74.46Â±9.86</td><td class="xbxx-borders">75.10Â±10.25</td><td class="xbxr-borders">74.75Â±10.07</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline in the Modified Intention-to-Treat Population.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plusâminus values are means Â±SD. Patients with a baseline estimated glomerular filtration rate (GFR) of less than 45 ml per minute per 1.73 m<sup>2</sup> were excluded from the trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t1fn2" role="paragraph">Race or ethnic group was reported by the patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t1fn3" role="paragraph">Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t1fn4" role="paragraph">The mean value of the estimated GFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t1fn5" role="paragraph">For the calculation of the urinary albumin-to-creatinine ratio, the amount of albumin measured in milligrams per deciliter was divided by the amount of creatinine measured in grams per deciliter.</div></div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2107519_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2107519_t2.jpg"><img src="/cms/10.1056/NEJMoa2107519/asset/10621e72-34da-439d-8636-52196bc57669/assets/images/large/nejmoa2107519_t2.jpg" height="2908" width="2617" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="6"><span>Tirzepatide</span></th><th class="txxx-borders" colspan="2"><span>Semaglutide</span></th><th class="txxr-borders" colspan="2"><span>Total<br>(N=1878)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>5 mg<br>(N=470)</span></th><th class="xxxx-borders" colspan="2"><span>10 mg<br>(N=469)</span></th><th class="xxxx-borders" colspan="2"><span>15 mg<br>(N=470)</span></th><th class="xxxx-borders" colspan="2"><span>1 mg<br>(N=469)</span></th><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">No. of <br>patients (%)</th><th class="xxxx-borders">No. of<br> events</th><th class="xxxx-borders">No. of<br> patients (%)</th><th class="xxxx-borders">No. of<br> events</th><th class="xxxx-borders">No. of<br> patients (%)</th><th class="xxxx-borders">No. of<br> events</th><th class="xxxx-borders">No. of <br>patients (%)</th><th class="xxxx-borders">No. of <br>events</th><th class="xxxx-borders">No. of <br>patients (%)</th><th class="xxxr-borders">No. of<br> events</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Patients with â¥1 adverse event</td><td class="xxxx-borders shading">299 (63.6)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">322 (68.7)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">324 (68.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">301 (64.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1246 (66.3)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Patients with â¥1 serious adverse event</td><td class="xxxx-borders">33 (7.0)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">25 (5.3)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">27 (5.7)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">13 (2.8)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">98 (5.2)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Death<a href="#t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">13 (0.7)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse events leading to discontinuation of tirzepatide or semaglutide</td><td class="xxxx-borders">28 (6.0)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">40 (8.5)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">40 (8.5)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">19 (4.1)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">127 (6.8)</td><td class="xxxr-borders">â</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Adverse events occurring in â¥0.2% of the overall population (i.e., 3 patients) and leading to discontinuation of tirzepatide or semaglutide</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">6 (1.3)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">7 (1.5)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">4 (0.9)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">4 (0.9)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">21 (1.1)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Vomiting</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">3 (0.6)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">12 (0.6)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">3 (0.6)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">6 (1.3)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">11 (0.6)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">9 (0.5)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Dyspepsia</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">0</td><td class="xxxx-borders">â</td><td class="xxxx-borders">5 (0.3)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">5 (0.3)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Fatigue</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">4 (0.2)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Elevated blood calcitonin level</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">3 (0.2)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Constipation</td><td class="xxxx-borders">0</td><td class="xxxx-borders">â</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">0</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">3 (0.2)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Covid-19ârelated pneumonia</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">3 (0.2)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Injection-site reaction</td><td class="xxxx-borders">0</td><td class="xxxx-borders">â</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">0</td><td class="xxxx-borders">â</td><td class="xxxx-borders">3 (0.2)</td><td class="xxxr-borders">â</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Adverse events occurring in â¥5% of patients in any treatment group, according to preferred term</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">82 (17.4)</td><td class="xxxx-borders">111</td><td class="xxxx-borders">90 (19.2)</td><td class="xxxx-borders">124</td><td class="xxxx-borders">104 (22.1)</td><td class="xxxx-borders">136</td><td class="xxxx-borders">84 (17.9)</td><td class="xxxx-borders">126</td><td class="xxxx-borders">360 (19.2)</td><td class="xxxr-borders">497</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">62 (13.2)</td><td class="xxxx-borders shading">120</td><td class="xxxx-borders shading">77 (16.4)</td><td class="xxxx-borders shading">99</td><td class="xxxx-borders shading">65 (13.8)</td><td class="xxxx-borders shading">102</td><td class="xxxx-borders shading">54 (11.5)</td><td class="xxxx-borders shading">68</td><td class="xxxx-borders shading">258 (13.7)</td><td class="xxxr-borders shading">389</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xxxx-borders">27 (5.7)</td><td class="xxxx-borders">35</td><td class="xxxx-borders">40 (8.5)</td><td class="xxxx-borders">56</td><td class="xxxx-borders">46 (9.8)</td><td class="xxxx-borders">61</td><td class="xxxx-borders">39 (8.3)</td><td class="xxxx-borders">53</td><td class="xxxx-borders">152 (8.1)</td><td class="xxxr-borders">205</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Dyspepsia</td><td class="xxxx-borders shading">34 (7.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">29 (6.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">43 (9.1)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">31 (6.6)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">137 (7.3)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders">35 (7.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">34 (7.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">42 (8.9)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">25 (5.3)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">136 (7.2)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">32 (6.8)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">21 (4.5)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">21 (4.5)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">27 (5.8)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">101 (5.4)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders">14 (3.0)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">21 (4.5)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">24 (5.1)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">24 (5.1)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">83 (4.4)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">All gastrointestinal adverse events</td><td class="xxxx-borders shading">188 (40.0)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">216 (46.1)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">211 (44.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">193 (41.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">808 (43.0)</td><td class="xxxr-borders shading">â</td></tr><tr data-type="row"><td class="xxlx-borders">Other adverse events</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hypoglycemia, blood glucose level &lt;54 mg/dl</td><td class="xxxx-borders shading">3 (0.6)</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">8 (1.7)</td><td class="xxxx-borders shading">10</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">14 (0.7)</td><td class="xxxr-borders shading">17</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Severe hypoglycemia</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.2)<a href="#t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">1<a href="#t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (0.1)</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Injection-site reaction</td><td class="xxxx-borders shading">9 (1.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">13 (2.8)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">21 (4.5)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">44 (2.3)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjudicated pancreatitis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">â</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">3 (0.6)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">7 (0.4)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Cholelithiasis</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">14 (0.7)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hypersensitivity<a href="#t2fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">9 (1.9)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">13 (2.8)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">8 (1.7)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">11 (2.3)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">41 (2.2)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Diabetic retinopathy<a href="#t2fn5" role="doc-noteref">Â¶</a></td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">â</td><td class="xbxx-borders shading">2 (0.4)</td><td class="xbxx-borders shading">â</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">â</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">â</td><td class="xbxx-borders shading">2 (0.1)</td><td class="xbxr-borders shading">â</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events and Safety.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Patients may be counted in more than one category. The number of events was reported if available. To convert blood glucose values to millimoles per liter, multiply by 0.05551.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t2fn2" role="paragraph">Deaths are also included as serious adverse events and discontinuations due to adverse events. No deaths were considered by the investigators to be related to tirzepatide or semaglutide. All deaths were adjudicated by an external committee of physicians with cardiology expertise.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t2fn3" role="paragraph">This patient had a hypoglycemic event that was not considered by the investigator to be severe, but it was reported as a serious adverse event.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t2fn4" role="paragraph">This category includes immediate (&lt;24 hours after trial drug administration) and nonimmediate (&gt;24 hours after trial drug administration) hypersensitivity events. One immediate event was reported in the tirzepatide 15-mg group.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t2fn5" role="paragraph">Diabetic retinopathy was confirmed by funduscopic examination.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Glycemic End Points</h3><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">At 40 weeks, reductions in the mean glycated hemoglobin level with tirzepatide at a dose of 5 mg, 10 mg, and 15 mg were â2.01 percentage points, â2.24 percentage points, and â2.30 percentage points, respectively, as compared with â1.86 percentage points with semaglutide (<a href="#f1">Figure 1A</a>). All tirzepatide doses were found to be superior to semaglutide, with estimated treatment differences of â0.15 percentage points (95% confidence interval [CI], â0.28 to â0.03; P=0.02) with tirzepatide 5 mg, â0.39 percentage points (95% CI, â0.51 to â0.26; P&lt;0.001) with tirzepatide 10 mg, and â0.45 percentage points (95% CI, â0.57 to â0.32; P&lt;0.001) with tirzepatide 15 mg.</span> The glycated hemoglobin level over time is shown in (<a href="#f1">Figure 1B</a>). A total of 82 to 86% of the patients who received tirzepatide and 79% of those who received semaglutide had a decrease in the glycated hemoglobin level to less than 7.0%. A total of 69 to 80% of the patients who received tirzepatide and 64% of those who received semaglutide had a decrease in the glycated hemoglobin level to 6.5% or less, and 27 to 46% and 19%, respectively, had a decrease in the glycated hemoglobin level to less than 5.7% (Fig. 1C). A subgroup analysis involving patients with a glycated hemoglobin level above 8.5% showed mean reductions in the glycated hemoglobin level of â3.22 percentage points with tirzepatide at a dose of 15 mg as compared with â2.68 percentage points with semaglutide (Fig. S8).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f1.jpg"><img src="/cms/10.1056/NEJMoa2107519/asset/cb8606e2-07b4-4eb5-8a7f-c9349641ebd8/assets/images/large/nejmoa2107519_f1.jpg" height="2442" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Effect of Once-Weekly Tirzepatide, as Compared with Semaglutide, on the Glycated Hemoglobin Level, Percentage of Patients Who Met Glycated Hemoglobin Level Targets, and Fasting Serum Glucose Levels.</div><div class="notes"><div role="doc-footnote">Least-squares means (Â±SE) are presented, unless otherwise noted. Error bars indicate the standard error. Estimated treatment differences (ETDs) are least-squares means (95% confidence interval) at 40 weeks in the modified intention-to-treat population. Panel A shows the change from baseline in the glycated hemoglobin level at 40 weeks, as assessed with the use of analysis of covariance with multiple imputation according to treatment for the missing glycated hemoglobin level at 40 weeks (treatment-regimen estimand). Panel B shows the values for glycated hemoglobin levels over time, derived from a mixed-model repeated-measures analysis (efficacy estimand). Arrows indicate the times at which the maintenance doses of tirzepatide (5 mg, 10 mg, or 15 mg) and semaglutide 1 mg were achieved. Panel C shows the percentage of patients who met glycated hemoglobin level targets of less than 7.0%, 6.5% or less, and less than 5.7% at 40 weeks (treatment-regimen estimand). The percentage was calculated with the use of Rubinâs rules by combining the percentages of patients who met the target in imputed data sets. The glycated hemoglobin levels of 6.5% or less and less than 5.7% (tirzepatide 5-mg group only) were not controlled for type 1 errors; thus, P values are not presented. Panel D shows fasting serum glucose values over time, derived from mixed-model repeated-measures analysis (efficacy estimand). Arrows indicate the times at which the maintenance doses of tirzepatide (5 mg, 10 mg, or 15 mg) and semaglutide 1 mg were achieved.</div></div></figcaption></figure></div><div role="paragraph">With the use of the efficacy estimand at 40 weeks, greater reductions in the fasting serum glucose level were observed with all tirzepatide doses than with semaglutide (<a href="#f1">Figure 1D</a> and Fig. S9). In addition, all the tirzepatide doses resulted in greater reductions than those with semaglutide in the patient-measured mean blood glucose levels at all seven time points (Fig. S10A). Reductions from baseline in the mean daily 2-hour postprandial glucose level from the seven-point blood glucose profile ranged from â71.6 to â81.9 mg per deciliter (â4.0 to â4.5 mmol per liter) with tirzepatide to â67.2 mg per deciliter (â3.7 mmol per liter) with semaglutide (Fig. S10B).</div></section><section id="sec-2-3"><h3>Body-Weight End Points</h3><div role="paragraph">Reductions in body weight with tirzepatide were dose-dependent (<a href="#f2">Figure 2A and 2B</a>). At 40 weeks, the mean reductions in body weight with tirzepatide at a dose of 5 mg, 10 mg, and 15 mg were â7.6 kg, â9.3 kg, and â11.2 kg, respectively, as compared with â5.7 kg with semaglutide. At all doses, tirzepatide was superior to semaglutide, with estimated treatment differences of â1.9 kg (95% CI, â2.8 to â1.0) with tirzepatide at a dose of 5 mg, â3.6 kg (95% CI, â4.5 to â2.7) with tirzepatide at a dose of 10 mg, and â5.5 kg (95% CI, â6.4 to â4.6) with tirzepatide at a dose of 15 mg (P&lt;0.001 for all comparisons). A total of 65 to 80% of the patients who received tirzepatide and 54% of those who received semaglutide had reductions in body weight of at least 5%; 34 to 57% and 24%, respectively, had reductions of at least 10%; and 15 to 36% and 8%, respectively, had reductions of at least 15% (<a href="#f2">Figure 2C</a>). With the use of the efficacy estimand, more patients who received tirzepatide than those who received semaglutide met a composite end point of a glycated hemoglobin level of 6.5% or less with at least 10% weight loss and without clinically significant hypoglycemia (blood glucose level, &lt;54 mg per deciliter) or severe hypoglycemia (32 to 60% vs. 22%, respectively) (Table S5). The mean BMI and waist circumference over time are shown in Fig. S11.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f2.jpg"><img src="/cms/10.1056/NEJMoa2107519/asset/aef32ee9-ba38-45e0-86dc-a9d7ac0164fc/assets/images/large/nejmoa2107519_f2.jpg" height="2281" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Effect of Once-Weekly Tirzepatide, as Compared with Semaglutide, on Body Weight, the Percentage of Patients Who Met Weight-Loss Goals, and the Lipid Profile.</div><div class="notes"><div role="doc-footnote">Least-squares means (Â±SE) are presented, unless otherwise noted. Error bars indicate the standard error. Panel A shows the change from baseline in body weight at 40 weeks, as assessed with analysis of covariance with multiple imputation for treatment for missing weight at 40 weeks (treatment-regimen estimand). ETDs are least-squares means (95% confidence interval) at 40 weeks in the modified intention-to-treat population. Panel B shows the change from baseline in body weight over time, derived from a mixed-model repeated-measures analysis (efficacy estimand). The percent changes from baseline values at 40 weeks are shown in parentheses. Arrows indicate the times at which the maintenance doses of tirzepatide (5 mg, 10 mg, or 15 mg) and semaglutide 1 mg were achieved. Panel C shows the percentage of patients who had body-weight reductions of at least 5%, 10%, or 15% from baseline to week 40 (treatment-regimen estimand). The percentage was calculated with the use of Rubinâs rules by combining the percentages of patients who met the target in imputed data sets. Panel D shows the percent change (Â±SE) from baseline in lipid levels at 40 weeks, as estimated with the use of log transformation. HDL denotes high-density lipoprotein, LDL low-density lipoprotein, and VLDL very-low-density lipoprotein.</div></div></figcaption></figure></div></section><section id="sec-2-4"><h3>Other End Points and Safety</h3><div role="paragraph"><a id="exam-tint-three-c"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="three-c">At 40 weeks, the triglyceride and serum very-low-density lipoprotein levels were lower and the high-density lipoprotein cholesterol levels were higher in patients who received tirzepatide than in those who received semaglutide (<a href="#f2">Figure 2D</a>, Fig. S12, and Table S6). The total cholesterol and low-density lipoprotein cholesterol levels did not differ significantly among the treatment groups.</span></div><div role="paragraph">The percentages of patients who reported any adverse events were similar in the four treatment groups (<a href="#t2">Table 2</a>). There was a higher number of serious adverse events among patients who received tirzepatide than among those who received semaglutide (<a href="#t2">Table 2</a> and Table S7); the most frequent serious adverse event was coronavirus disease 2019 (Covid-19)ârelated pneumonia in all groups.</div><div role="paragraph"><a id="exam-tint-three-a"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="three-a">The most frequent adverse events reported were gastrointestinal-related events (<a href="#t2">Table 2</a>).</span> Nausea was reported in 17 to 22% of patients who received tirzepatide and in 18% who received semaglutide, diarrhea was reported in 13 to 16% and 12%, respectively, vomiting in 6 to 10% and 8%, respectively, and decreased appetite in 7 to 9% and 5%. Most cases of nausea, vomiting, and diarrhea were mild to moderate in severity and transient and occurred during the dose-escalation period in all groups (Fig. S13 and Tables S8 and S9).</div><div role="paragraph">A total of 13 deaths (0.7%) occurred in the total population during the trial (4 patients in each of the three tirzepatide groups and 1 patient in the semaglutide group) (<a href="#t2">Table 2</a>). None of the deaths were considered by the investigators to be related to tirzepatide or semaglutide. All the deaths were adjudicated by an external committee of physicians. Five deaths were related to Covid-19, and the death of a sixth patient with suspected Covid-19 was adjudicated as being from cardiovascular causes. These 6 deaths occurred in 1 patient who received tirzepatide at a dose of 5 mg, 2 patients who received tirzepatide at a dose of 10 mg, 2 patients (including the patient with presumptive Covid-19) who received tirzepatide at a dose of 15 mg, and 1 patient who received semaglutide. Four other deaths were adjudicated as cardiovascular-related deaths (1 in the tirzepatide 5-mg group, 1 in the tirzepatide 10-mg group, 2 in the tirzepatide 15-mg group, and none in the semaglutide group), and 2 deaths were considered to be indeterminate (1 each in the tirzepatide 5-mg and 10-mg groups) (Table S10). Of these 2 patients with deaths that were considered to be indeterminate, 1 had coronary artery disease. Two patients with cardiovascular-related deaths had no previous cardiovascular risk factors other than type 2 diabetes.</div><div role="paragraph">Clinically significant hypoglycemia (blood glucose level, &lt;54 mg per deciliter) was reported in 3 patients (0.6%), 1 patient (0.2%), and 8 patients (1.7%) who received tirzepatide at a dose of 5 mg, 10 mg, and 15 mg, respectively, as compared with 2 patients (0.4%) who received semaglutide (<a href="#t2">Table 2</a>). Two events of severe hypoglycemia were reported (1 each in the tirzepatide 5-mg and 15-mg groups). Both patients recovered and completed the trial while receiving the assigned trial drug. Rescue therapy for persistent hyperglycemia was warranted for 1.3 to 1.5% of patients who received tirzepatide and 2.8% of those who received semaglutide.</div><div role="paragraph">Adjudication-confirmed cases of pancreatitis were reported in patients who received tirzepatide (2 cases each in the 10-mg and 15-mg groups) and in 3 patients who received semaglutide (<a href="#t2">Table 2</a>). No cases were serious. Changes in serum alanine aminotransferase levels ranged from â22 to â30% with tirzepatide as compared with â22% with semaglutide; and changes in aspartate aminotransferase ranged from and â9 to â14% with tirzepatide as compared with â9% with semaglutide (Table S11). Four patients from each tirzepatide group and 2 patients from the semaglutide group reported cholelithiasis (<a href="#t2">Table 2</a>). No clinically relevant changes in mean calcitonin levels were observed, and no cases of medullary thyroid cancer were reported. Two cases of diabetic retinopathy were reported (both with tirzepatide at a dose of 10 mg) (<a href="#t2">Table 2</a> and Table S12).</div><div role="paragraph">Transient increases in the mean pulse rate of 1.1 to 4.6 beats per minute were observed during the trial. At 40 weeks, the mean pulse rate had increased by 2.3 beats per minute with tirzepatide at a dose of 5 mg, by 2.2 beats per minute at a dose of 10 mg, and by 2.6 beats per minute at a dose of 15 mg, as compared with an increase of 2.5 beats per minute with semaglutide; the mean pulse rate did not differ significantly among the treatment groups (Fig. S14A). Systolic and diastolic blood pressure decreased with tirzepatide at a dose of 5 mg (â4.8 mm Hg and â1.9 mm Hg, respectively), at a dose of 10 mg (â5.3 mm Hg and â2.5 mm Hg, respectively), and at a dose of 15 mg (â6.5 mm Hg and â2.9 mm Hg, respectively) as compared with semaglutide (â3.6 mm Hg and â1.0 mm Hg, respectively) (Fig. S14B and C).</div><div role="paragraph">Hypersensitivity reactions occurred in 1.7 to 2.8% of the patients who received tirzepatide and in 2.3% of those who received semaglutide. Injection-site reactions occurred in 1.9 to 4.5% of the patients who received tirzepatide and in 0.2% of those who received semaglutide; these reactions were mild to moderate in severity (<a href="#t2">Table 2</a>). No serious cases of hypersensitivity or injection-site reactions were reported. Similar results for glycated hemoglobin level, body weight, and the percentage of patients who met the targets for glycated hemoglobin level and weight loss were reported with the efficacy estimand (<a href="#f1">Figure 1B</a> and <a href="#f2">Figure 2B</a>, and Fig. S15 and Table S13).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In the current trial, tirzepatide at a dose of 5 mg, 10 mg, or 15 mg was noninferior and superior to semaglutide at a dose of 1 mg, with respect to a reduction in the glycated hemoglobin level in patients with type 2 diabetes who were receiving metformin. <a id="exam-tint-three-b"></a><a id="exam-tint-three-d"></a><span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="three-b three-d">Tirzepatide was also superior to semaglutide with respect to reductions in body weight. A total of 82 to 86% of the patients who received tirzepatide and 79% of those who received semaglutide reached the glycated hemoglobin level target of less than 7.0% that is recommended by the American Diabetes Association and the European Association for the Study of Diabetes.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21" href-manipulated="true" aria-label="Reference 21">21</a></sup> The glycated hemoglobin level target of less than 5.7% (normoglycemia) was met in 27 to 46% of the patients who received tirzepatide and in 19% of those who received semaglutide. The patients who received tirzepatide at a dose of 15 mg had almost twice the weight loss of those who received semaglutide at a dose of 1 mg. Weight reduction did not plateau in any of the four treatment groups at 40 weeks.</span></div><div role="paragraph">A glycated hemoglobin level of less than 5.7% without an increased risk of hypoglycemia has not been considered attainable with current treatment options. In our trial, this goal was met with a gastrointestinal-related side-effect profile that was similar to that reported with GLP-1 receptor agonists.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22" href-manipulated="true" aria-label="Reference 22">22</a></sup> In addition, many patients who received tirzepatide were noted to have an improved lipid profile as well as improved blood pressure, biomarkers of insulin sensitivity, and liver-enzyme levels. We speculate that dual agonism (glucose-dependent insulinotropic polypeptide receptor and GLP-1 receptor) may allow some patients to reach near-normal glycemia with potential long-term benefits. The SURPASS-4 trial (ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03730662" target="_blank">NCT03730662</a>), which compared tirzepatide with insulin glargine, enrolled patients with increased cardiovascular risk, and the SURPASS-CVOT trial (<a href="http://clinicaltrials.gov/show/NCT04255433" target="_blank">NCT04255433</a>) is ongoing to compare tirzepatide with dulaglutide and to provide a more comprehensive assessment of cardiovascular safety.</div><div role="paragraph">The dose-escalation scheme in the current trial of the phase 3 SURPASS clinical program, which included a lower starting dose and slower dose escalation in smaller increments,<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> was associated with a better gastrointestinal-related side-effect profile than the scheme in the phase 2 trial, which involved more rapid escalation.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-2" href-manipulated="true" aria-label="Reference 9">9</a></sup> Gastrointestinal adverse events reported with tirzepatide and semaglutide were consistent with those that would be expected with the GLP-1 receptor agonist class and were mostly mild to moderate and occurred during the escalation period with both trial drugs. The most common reason for premature discontinuation of tirzepatide or semaglutide was adverse events, which were more common with tirzepatide at a dose of 10 mg and 15 mg than with tirzepatide at a dose of 5 mg and with semaglutide. Although there were numerically more deaths with tirzepatide, Covid-19 was a confounder in five of the deaths and presumptively involved in a sixth death. Five deaths were adjudicated to be related to cardiovascular causes, all in the tirzepatide groups; in addition to type 2 diabetes, three of those patients had previous risk factors and established cardiovascular disease, and a fourth was a smoker and was overweight.</div><div role="paragraph">The limitations of our trial were that treatments could not be blinded because of differences in devices and dose-escalation schemes (tirzepatide doses were blinded) and the relatively short duration of 40 weeks, which allowed only 16 weeks at a steady state for the assessment of the highest tirzepatide dose. In addition, the number of Black patients was low. Higher doses of semaglutide were not available as comparators at the time of this trial.</div><div role="paragraph">Our trial has several strengths. The reductions in glycated hemoglobin level and body weight observed with semaglutide were consistent with the results already reported in the SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) clinical trial program.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11 r12 r13 r14 r15 r16 r17 r19" id="body-ref-r19-2" href-manipulated="true">10â17,19</a></sup> In addition, in the 68-week STEP 2 (Semaglutide Treatment Effect in People with Obesity) trial, which assessed semaglutide at doses of 1 mg and 2.4 mg in addition to lifestyle intervention for long-term weight management in patients with type 2 diabetes, the estimated treatment difference in weight loss was â2.7 percentage points with semaglutide at a dose of 2.4 mg as compared with semaglutide at a dose of 1 mg (â9.6% vs. â7.0%) and â6.2 percentage points with semaglutide at a dose of 2.4 mg as compared with placebo (â9.6% vs. â3.4%).<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup> These results are consistent with those reported in our trial with semaglutide at a dose of 1 mg for weight reduction. Other strengths of our trial include an active comparator (semaglutide at a dose of 1 mg) and a large sample size with a large number of patients who completed the trial.</div><div role="paragraph">In patients with type 2 diabetes who were receiving metformin, the novel once-weekly dual glucose-dependent insulinotropic polypeptideâGLP-1 receptor agonist tirzepatide was noninferior and superior to the selective GLP-1 receptor agonist semaglutide (at a dose of 1 mg) with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on June 25, 2021, and updated on July 15, 2021, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Presented in part at the Virtual 81st Scientific Sessions of the American Diabetes Association (June 25â29, 2021).</div><div role="paragraph">Supported by Eli <span class="named-content" data-type="funder">Lilly</span>.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank Weiguo Zhu and Xiaonan Guo (Eli Lilly) for their contributions to the data preparation and analysis and Chrisanthi A. Karanikas (Eli Lilly) for medical writing and editing assistance with an earlier draft of the manuscript.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2107519_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2107519/suppl_file/nejmoa2107519_research-summary.pdf" download="nejmoa2107519_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2107519_research-summary.pdf" data-doi="10.1056/NEJMoa2107519">Download</a></li><li>823.09 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2107519_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2107519/suppl_file/nejmoa2107519_protocol.pdf" download="nejmoa2107519_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2107519_protocol.pdf" data-doi="10.1056/NEJMoa2107519">Download</a></li><li>6.77 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2107519_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2107519/suppl_file/nejmoa2107519_appendix.pdf" download="nejmoa2107519_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2107519_appendix.pdf" data-doi="10.1056/NEJMoa2107519">Download</a></li><li>1.67 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2107519_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2107519/suppl_file/nejmoa2107519_disclosures.pdf" download="nejmoa2107519_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2107519_disclosures.pdf" data-doi="10.1056/NEJMoa2107519">Download</a></li><li>532.52 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2107519_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2107519/suppl_file/nejmoa2107519_data-sharing.pdf" download="nejmoa2107519_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2107519_data-sharing.pdf" data-doi="10.1056/NEJMoa2107519">Download</a></li><li>71.06 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">American Diabetes Association. Introduction: standards of medical care in diabetes â 2021. <em>Diabetes Care</em> 2021;44:Suppl 1:S1-S2.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc21-Sint" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33298409/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000609468800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Introduction%3A+standards+of+medical+care+in+diabetes+%E2%80%94+2021.&amp;publication_year=2021&amp;journal=Diabetes+Care&amp;pages=S1-S2&amp;doi=10.2337%2Fdc21-Sint&amp;pmid=33298409" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <em>Diabetologia</em> 2020;63:221-228.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00125-019-05039-w" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31853556/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000511867900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2019+update+to%3A+Management+of+hyperglycaemia+in+type+2+diabetes%2C+2018%3A+a+consensus+report+by+the+American+Diabetes+Association+%28ADA%29+and+the+European+Association+for+the+Study+of+Diabetes+%28EASD%29.&amp;publication_year=2020&amp;journal=Diabetologia&amp;pages=221-228&amp;doi=10.1007%2Fs00125-019-05039-w&amp;pmid=31853556" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">MÃ¼ller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). <em>Mol Metab</em> 2019;30:72-130.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.molmet.2019.09.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31767182/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000500474800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glucagon-like+peptide+1+%28GLP-1%29.&amp;publication_year=2019&amp;journal=Mol+Metab&amp;pages=72-130&amp;doi=10.1016%2Fj.molmet.2019.09.010&amp;pmid=31767182" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Christensen M, Vedtofte L, Holst JJ, VilsbÃ¸ll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. <em>Diabetes</em> 2011;60:3103-3109.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/db11-0979" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21984584/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297715100003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glucose-dependent+insulinotropic+polypeptide%3A+a+bifunctional+glucose-dependent+regulator+of+glucagon+and+insulin+secretion+in+humans.&amp;publication_year=2011&amp;journal=Diabetes&amp;pages=3103-3109&amp;doi=10.2337%2Fdb11-0979&amp;pmid=21984584" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Yip RG, Boylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocytes. <em>Endocrinology</em> 1998;139:4004-4007.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1210/endo.139.9.6288" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9724057/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000075500500042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Functional+GIP+receptors+are+present+on+adipocytes.&amp;publication_year=1998&amp;journal=Endocrinology&amp;pages=4004-4007&amp;doi=10.1210%2Fendo.139.9.6288&amp;pmid=9724057" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? <em>Trends Endocrinol Metab</em> 2020;31:410-421.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.tem.2020.02.006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32396843/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000532680200005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=How+may+GIP+enhance+the+therapeutic+efficacy+of+GLP-1%3F&amp;publication_year=2020&amp;journal=Trends+Endocrinol+Metab&amp;pages=410-421&amp;doi=10.1016%2Fj.tem.2020.02.006&amp;pmid=32396843" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] which may prevent ectopic fat deposition. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] a GLP-1âinduced reduction in food intake. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. <em>Mol Metab</em> 2018;18:3-14.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.molmet.2018.09.009" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30473097/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450929200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=LY3298176%2C+a+novel+dual+GIP+and+GLP-1+receptor+agonist+for+the+treatment+of+type+2+diabetes+mellitus%3A+from+discovery+to+clinical+proof+of+concept.&amp;publication_year=2018&amp;journal=Mol+Metab&amp;pages=3-14&amp;doi=10.1016%2Fj.molmet.2018.09.009&amp;pmid=30473097" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a GLP-1âinduced reduction in food intake. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and includes a C20 fatty diacid moiety. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] once-weekly subcutaneous administration. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. <em>Cell Metab</em> 2021;33(4):833.e5-844.e5.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cmet.2021.01.015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33571454/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000637370500017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+glucose-dependent+insulinotropic+polypeptide+%28GIP%29+regulates+body+weight+and+food+intake+via+CNS-GIPR+signaling.&amp;publication_year=2021&amp;journal=Cell+Metab&amp;pages=833.e5-844.e5&amp;doi=10.1016%2Fj.cmet.2021.01.015&amp;pmid=33571454" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. <em>Lancet</em> 2018;392:2180-2193.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)32260-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30293770/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450358900030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+LY3298176%2C+a+novel+dual+GIP+and+GLP-1+receptor+agonist%2C+in+patients+with+type+2+diabetes%3A+a+randomised%2C+placebo-controlled+and+active+comparator-controlled+phase+2+trial.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=2180-2193&amp;doi=10.1016%2FS0140-6736%2818%2932260-8&amp;pmid=30293770" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] hemoglobin level and weight at 26 weeks. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] which involved more rapid escalation. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">AhrÃ©n B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. <em>Lancet Diabetes Endocrinol</em> 2017;5:341-354.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(17)30092-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28385659/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once-weekly+semaglutide+versus+once-daily+sitagliptin+as+an+add-on+to+metformin%2C+thiazolidinediones%2C+or+both%2C+in+patients+with+type+2+diabetes+%28SUSTAIN+2%29%3A+a+56-week%2C+double-blind%2C+phase+3a%2C+randomised+trial.&amp;publication_year=2017&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=341-354&amp;doi=10.1016%2FS2213-8587%2817%2930092-X&amp;pmid=28385659" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. <em>Lancet Diabetes Endocrinol</em> 2018;6:275-286.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(18)30024-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29397376/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Semaglutide+versus+dulaglutide+once+weekly+in+patients+with+type+2+diabetes+%28SUSTAIN+7%29%3A+a+randomised%2C+open-label%2C+phase+3b+trial.&amp;publication_year=2018&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=275-286&amp;doi=10.1016%2FS2213-8587%2818%2930024-X&amp;pmid=29397376" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Sorli C, Harashima S-I, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. <em>Lancet Diabetes Endocrinol</em> 2017;5:251-260.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(17)30013-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28110911/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once-weekly+semaglutide+monotherapy+versus+placebo+in+patients+with+type+2+diabetes+%28SUSTAIN+1%29%3A+a+double-blind%2C+randomised%2C+placebo-controlled%2C+parallel-group%2C+multinational%2C+multicentre+phase+3a+trial.&amp;publication_year=2017&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=251-260&amp;doi=10.1016%2FS2213-8587%2817%2930013-X&amp;pmid=28110911" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. <em>Lancet Diabetes Endocrinol</em> 2019;7:356-367.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(19)30066-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30833170/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Semaglutide+once+weekly+as+add-on+to+SGLT-2+inhibitor+therapy+in+type+2+diabetes+%28SUSTAIN+9%29%3A+a+randomised%2C+placebo-controlled+trial.&amp;publication_year=2019&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=356-367&amp;doi=10.1016%2FS2213-8587%2819%2930066-X&amp;pmid=30833170" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. <em>Diabetes Care</em> 2018;41:258-266.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc17-0417" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29246950/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430455100015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once-weekly+semaglutide+versus+exenatide+ER+in+subjects+with+type+2+diabetes+%28SUSTAIN+3%29%3A+a+56-week%2C+open-label%2C+randomized+clinical+trial.&amp;publication_year=2018&amp;journal=Diabetes+Care&amp;pages=258-266&amp;doi=10.2337%2Fdc17-0417&amp;pmid=29246950" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. <em>Lancet Diabetes Endocrinol</em> 2017;5:355-366.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(17)30085-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28344112/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once-weekly+semaglutide+versus+once-daily+insulin+glargine+as+add-on+to+metformin+%28with+or+without+sulfonylureas%29+in+insulin-naive+patients+with+type+2+diabetes+%28SUSTAIN+4%29%3A+a+randomised%2C+open-label%2C+parallel-group%2C+multicentre%2C+multinational%2C+phase+3a+trial.&amp;publication_year=2017&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=355-366&amp;doi=10.1016%2FS2213-8587%2817%2930085-2&amp;pmid=28344112" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. <em>J Clin Endocrinol Metab</em> 2018;103:2291-2301.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1210/jc.2018-00070" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29688502/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000434881400026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Semaglutide+added+to+basal+insulin+in+type+2+diabetes+%28SUSTAIN+5%29%3A+a+randomized%2C+controlled+trial.&amp;publication_year=2018&amp;journal=J+Clin+Endocrinol+Metab&amp;pages=2291-2301&amp;doi=10.1210%2Fjc.2018-00070&amp;pmid=29688502" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Lingvay I, Catarig A-M, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. <em>Lancet Diabetes Endocrinol</em> 2019;7:834-844.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(19)30311-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31540867/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once-weekly+semaglutide+versus+daily+canagliflozin+as+add-on+to+metformin+in+patients+with+type+2+diabetes+%28SUSTAIN+8%29%3A+a+double-blind%2C+phase+3b%2C+randomised+controlled+trial.&amp;publication_year=2019&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=834-844&amp;doi=10.1016%2FS2213-8587%2819%2930311-0&amp;pmid=31540867" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. <em>N Engl J Med</em> 2016;375:1834-1844.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_19_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2107519&amp;key=10.1056%2FNEJMoa1607141&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27633186/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387534200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Semaglutide+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=1834-1844&amp;doi=10.1056%2FNEJMoa1607141&amp;pmid=27633186" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Capehorn MS, Catarig A-M, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). <em>Diabetes Metab</em> 2020;46:100-109.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.diabet.2019.101117" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31539622/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000528270300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once-weekly+semaglutide+1.0+mg+vs+once-daily+liraglutide+1.2+mg+as+add-on+to+1-3+oral+antidiabetic+drugs+in+subjects+with+type+2+diabetes+%28SUSTAIN+10%29.&amp;publication_year=2020&amp;journal=Diabetes+Metab&amp;pages=100-109&amp;doi=10.1016%2Fj.diabet.2019.101117&amp;pmid=31539622" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Ozempic: USPI product information. Bagsvaerd, Denmark: Novo Nordisk, 2021 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ozempic%3A+USPI+product+information&amp;publication_year=2021" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Davies MJ, DâAlessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <em>Diabetes Care</em> 2018;41:2669-2701.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci18-0033" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30291106/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450560000037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Management+of+hyperglycemia+in+type+2+diabetes%2C+2018%3A+a+consensus+report+by+the+American+Diabetes+Association+%28ADA%29+and+the+European+Association+for+the+Study+of+Diabetes+%28EASD%29.&amp;publication_year=2018&amp;journal=Diabetes+Care&amp;pages=2669-2701&amp;doi=10.2337%2Fdci18-0033&amp;pmid=30291106" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Meier JJ, Nauck MA. Incretin-based therapies: where will we be 50 years from now? <em>Diabetologia</em> 2015;58:1745-1750.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00125-015-3608-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25994073/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000358877300013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Incretin-based+therapies%3A+where+will+we+be+50+years+from+now%3F&amp;publication_year=2015&amp;journal=Diabetologia&amp;pages=1745-1750&amp;doi=10.1007%2Fs00125-015-3608-6&amp;pmid=25994073" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. <em>Diabetes Obes Metab</em> 2020;22:938-946.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/dom.13979" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31984598/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000512459700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+tolerability+of+tirzepatide%2C+a+dual+glucose-dependent+insulinotropic+peptide+and+glucagon-like+peptide-1+receptor+agonist+in+patients+with+type+2+diabetes%3A+a+12-week%2C+randomized%2C+double-blind%2C+placebo-controlled+study+to+evaluate+different+dose-escalation+regimens.&amp;publication_year=2020&amp;journal=Diabetes+Obes+Metab&amp;pages=938-946&amp;doi=10.1111%2Fdom.13979&amp;pmid=31984598" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Davies M, FÃ¦rch L, Jeppesen OK, et al. Semaglutide 2Â·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. <em>Lancet</em> 2021;397:971-984.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)00213-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33667417/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000627814200026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Semaglutide+2%C2%B74+mg+once+a+week+in+adults+with+overweight+or+obesity%2C+and+type+2+diabetes+%28STEP+2%29%3A+a+randomised%2C+double-blind%2C+double-dummy%2C+placebo-controlled%2C+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=971-984&amp;doi=10.1016%2FS0140-6736%2821%2900213-0&amp;pmid=33667417" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/385/6"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">385</span></span> â¢ <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">6</span></span> â¢ <span property="datePublished">August 5, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">503</span>-<span property="pageEnd">515</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright Â© 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2107519" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2107519?sg=AbW1N">Chinese Translation ä¸­æç¿»è¯</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: June 25, 2021</div><div><b class="core-label">Published in issue</b>: August 5, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/chronic-kidney-disease" alt="View article keyword Chronic Kidney Disease" data-interactiontype="article_recirculation_click">Chronic Kidney Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/coronary-disease-myocardial-infarction" alt="View article keyword Coronary Disease/Myocardial Infarction" data-interactiontype="article_recirculation_click">Coronary Disease/Myocardial Infarction</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/diabetes" alt="View article keyword Diabetes" data-interactiontype="article_recirculation_click">Diabetes</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Juan P.</span> <span property="familyName">FrÃ­as</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9486-1255" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9486-1255</a></span>, <span property="author" typeof="Person"><span property="givenName">Melanie J.</span> <span property="familyName">Davies</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Julio</span> <span property="familyName">Rosenstock</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Federico C.</span> <span property="familyName">PÃ©rez Manghi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Laura</span> <span property="familyName">FernÃ¡ndez LandÃ³</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Brandon K.</span> <span property="familyName">Bergman</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bing</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Xuewei</span> <span property="familyName">Cui</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Katelyn</span> <span property="familyName">Brown</span>, <span property="honorificSuffix">Pharm.D.</span></span>, for <span property="author" typeof="Person">the SURPASS-2 Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre â both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones MetabÃ³licas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. FrÃ­as at the National Research Institute, 2010 Wilshire Blvd., Ste. 302, Los Angeles, CA 90057, or at <a href="mailto:juan.frias@nritrials.com">juan.frias@nritrials.com</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">The SURPASS-2 Investigators are listed in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">1096</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2107519" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="d0d45e04-f62d-77de-6693-e4bc44744798"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108190377" style="display:inline-block;">
                <img alt="Article has an altmetric score of 1448" src="https://badges.altmetric.com/?size=320&amp;score=1448&amp;types=mabvctwf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108190377">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_d0d45e04-f62d-77de-6693-e4bc44744798" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108190377&amp;tab=news">
          Picked up by <b>160</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108190377&amp;tab=blogs">
          Blogged by <b>10</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108190377&amp;tab=policy-documents">
          Referenced in <b>2</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108190377&amp;tab=twitter">
          Posted by <b>326</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108190377&amp;tab=patents">
          Referenced in <b>3</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108190377&amp;tab=facebook">
          On <b>5</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108190377&amp;tab=wikipedia">
          Referenced in <b>16</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108190377&amp;tab=reddit">
          Reddited by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108190377&amp;tab=video">
          On <b>3</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=108190377&amp;tab=guidelines">
          Referenced in <b>3</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>1198</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d691a370eaf256-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2107519"> <input type="hidden" name="downloadFileName" value="csp_385_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2107519%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-6%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="1096" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">M.C. Ningtyas, </li><li class="list-inline-item cited-by__entry__author">B.A. Ansharullah, </li><li class="list-inline-item cited-by__entry__author">H. Sutanto, </li><li class="list-inline-item cited-by__entry__author">J.H. Prajitno, </li></ul><span class="cited-by__entry__title">Beyond weight: Exploring the nexus between obesity and osteoarthritis, </span><span class="cited-by__entry__series-title">Medicina de Familia. SEMERGEN, </span><span class="cited-by__entry__volume"><strong>51</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(102526), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.semerg.2025.102526" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.semerg.2025.102526</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.semerg.2025.102526" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yifang Yang, </li><li class="list-inline-item cited-by__entry__author">Qing Lin, </li></ul><span class="cited-by__entry__title">Design of potent and proteolytically stable double biaryl-stapled GLP-1R/GIPR peptide dual agonists, </span><span class="cited-by__entry__series-title">Bioorganic &amp; Medicinal Chemistry, </span><span class="cited-by__entry__volume"><strong>125</strong>, </span><span class="cited-by__entry__page-range">(118215), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.bmc.2025.118215" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.bmc.2025.118215</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.bmc.2025.118215" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Barry E. Levin, </li><li class="list-inline-item cited-by__entry__author">Nori Geary, </li><li class="list-inline-item cited-by__entry__author">Thomas A. Lutz, </li></ul><span class="cited-by__entry__title">The (dys)regulation of energy storage in obesity, </span><span class="cited-by__entry__series-title">Physiological Reviews, </span><span class="cited-by__entry__volume"><strong>105</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(803-895), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1152/physrev.00002.2024" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1152/physrev.00002.2024</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1152/physrev.00002.2024" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Elham Sadeghi, </li><li class="list-inline-item cited-by__entry__author">Elham Rahmanipour, </li><li class="list-inline-item cited-by__entry__author">Nicola Valsecchi, </li><li class="list-inline-item cited-by__entry__author">Saloni Kapoor, </li><li class="list-inline-item cited-by__entry__author">Maria Vittoria Cicinelli, </li><li class="list-inline-item cited-by__entry__author">Jay Chhablani, </li></ul><span class="cited-by__entry__title">An update on ocular effects of antidiabetic medications, </span><span class="cited-by__entry__series-title">Survey of Ophthalmology, </span><span class="cited-by__entry__volume"><strong>70</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(704-712), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.survophthal.2025.01.010" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.survophthal.2025.01.010</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.survophthal.2025.01.010" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Toshimasa Yamauchi, </li><li class="list-inline-item cited-by__entry__author">Taro Asakura, </li><li class="list-inline-item cited-by__entry__author">Tomotaka Shingaki, </li><li class="list-inline-item cited-by__entry__author">Tomonori Oura, </li><li class="list-inline-item cited-by__entry__author">Hideki Katagiri, </li></ul><span class="cited-by__entry__title">
              Efficacy and safety of onceâweekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the
              SURMOUNT
              â2 trial
            , </span><span class="cited-by__entry__series-title">Diabetes, Obesity and Metabolism, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/dom.16500" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/dom.16500</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/dom.16500" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Shuying Xie, </li><li class="list-inline-item cited-by__entry__author">Lan Ye, </li><li class="list-inline-item cited-by__entry__author">Anyuan Yang, </li><li class="list-inline-item cited-by__entry__author">Xiaoyan Li, </li><li class="list-inline-item cited-by__entry__author">Ying Yin, </li></ul><span class="cited-by__entry__title">Efficacy of Semaglutide Injection in the Treatment of Type 2 Diabetes
                    Mellitus and its Impact on C-Peptide Levels, </span><span class="cited-by__entry__series-title">Hormone and Metabolic Research, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1055/a-2618-7509" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1055/a-2618-7509</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1055/a-2618-7509" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Richard J MacIsaac, </li></ul><span class="cited-by__entry__title">Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome, </span><span class="cited-by__entry__series-title">Future Cardiology, </span><span class="cited-by__entry__page-range">(1-21), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/14796678.2025.2511412" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/14796678.2025.2511412</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/14796678.2025.2511412" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Tristan C. Dinsmore, </li><li class="list-inline-item cited-by__entry__author">Jacob E. Cortigiano, </li><li class="list-inline-item cited-by__entry__author">Siyuan Xiang, </li><li class="list-inline-item cited-by__entry__author">Marina V. Spenciner, </li><li class="list-inline-item cited-by__entry__author">Alexandra R. Dobbins, </li><li class="list-inline-item cited-by__entry__author">Richard L. Zhao, </li><li class="list-inline-item cited-by__entry__author">Brett M. Waldman, </li><li class="list-inline-item cited-by__entry__author">Martin Beinborn, </li><li class="list-inline-item cited-by__entry__author">Krishna Kumar, </li></ul><span class="cited-by__entry__title">Molecular Design of Unimolecular Tetra-Receptor Agonists, </span><span class="cited-by__entry__series-title">Journal of the American Chemical Society, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1021/jacs.5c04095" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1021/jacs.5c04095</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1021/jacs.5c04095" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Isabelle R. Miousse, </li></ul><span class="cited-by__entry__title">GLP-1 receptor agonists in the context of cancer: the road ahead, </span><span class="cited-by__entry__series-title">American Journal of Physiology-Cell Physiology, </span><span class="cited-by__entry__volume"><strong>328</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(C1822-C1828), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1152/ajpcell.00245.2025" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1152/ajpcell.00245.2025</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1152/ajpcell.00245.2025" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Panupong Hansrivijit, </li><li class="list-inline-item cited-by__entry__author">Janinne Ortega-Montiel, </li><li class="list-inline-item cited-by__entry__author">Deborah J. Wexler, </li><li class="list-inline-item cited-by__entry__author">Elisabetta Patorno, </li><li class="list-inline-item cited-by__entry__author">Julie M. Paik, </li></ul><span class="cited-by__entry__title">Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes, </span><span class="cited-by__entry__series-title">Kidney Medicine, </span><span class="cited-by__entry__volume"><strong>7</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(101013), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.xkme.2025.101013" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.xkme.2025.101013</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.xkme.2025.101013" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2107519%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-6%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2107519" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2107519" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2107519.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f0.jpg"><img src="/cms/10.1056/NEJMoa2107519/asset/3224f90f-0e67-4064-b4c3-5a2a1ba8a7b4/assets/images/large/nejmoa2107519_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f1.jpg"><img src="/cms/10.1056/NEJMoa2107519/asset/cb8606e2-07b4-4eb5-8a7f-c9349641ebd8/assets/images/large/nejmoa2107519_f1.jpg" height="2442" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Effect of Once-Weekly Tirzepatide, as Compared with Semaglutide, on the Glycated Hemoglobin Level, Percentage of Patients Who Met Glycated Hemoglobin Level Targets, and Fasting Serum Glucose Levels.</div><div class="notes"><div role="doc-footnote">Least-squares means (Â±SE) are presented, unless otherwise noted. Error bars indicate the standard error. Estimated treatment differences (ETDs) are least-squares means (95% confidence interval) at 40 weeks in the modified intention-to-treat population. Panel A shows the change from baseline in the glycated hemoglobin level at 40 weeks, as assessed with the use of analysis of covariance with multiple imputation according to treatment for the missing glycated hemoglobin level at 40 weeks (treatment-regimen estimand). Panel B shows the values for glycated hemoglobin levels over time, derived from a mixed-model repeated-measures analysis (efficacy estimand). Arrows indicate the times at which the maintenance doses of tirzepatide (5 mg, 10 mg, or 15 mg) and semaglutide 1 mg were achieved. Panel C shows the percentage of patients who met glycated hemoglobin level targets of less than 7.0%, 6.5% or less, and less than 5.7% at 40 weeks (treatment-regimen estimand). The percentage was calculated with the use of Rubinâs rules by combining the percentages of patients who met the target in imputed data sets. The glycated hemoglobin levels of 6.5% or less and less than 5.7% (tirzepatide 5-mg group only) were not controlled for type 1 errors; thus, P values are not presented. Panel D shows fasting serum glucose values over time, derived from mixed-model repeated-measures analysis (efficacy estimand). Arrows indicate the times at which the maintenance doses of tirzepatide (5 mg, 10 mg, or 15 mg) and semaglutide 1 mg were achieved.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f2.jpg"><img src="/cms/10.1056/NEJMoa2107519/asset/aef32ee9-ba38-45e0-86dc-a9d7ac0164fc/assets/images/large/nejmoa2107519_f2.jpg" height="2281" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Effect of Once-Weekly Tirzepatide, as Compared with Semaglutide, on Body Weight, the Percentage of Patients Who Met Weight-Loss Goals, and the Lipid Profile.</div><div class="notes"><div role="doc-footnote">Least-squares means (Â±SE) are presented, unless otherwise noted. Error bars indicate the standard error. Panel A shows the change from baseline in body weight at 40 weeks, as assessed with analysis of covariance with multiple imputation for treatment for missing weight at 40 weeks (treatment-regimen estimand). ETDs are least-squares means (95% confidence interval) at 40 weeks in the modified intention-to-treat population. Panel B shows the change from baseline in body weight over time, derived from a mixed-model repeated-measures analysis (efficacy estimand). The percent changes from baseline values at 40 weeks are shown in parentheses. Arrows indicate the times at which the maintenance doses of tirzepatide (5 mg, 10 mg, or 15 mg) and semaglutide 1 mg were achieved. Panel C shows the percentage of patients who had body-weight reductions of at least 5%, 10%, or 15% from baseline to week 40 (treatment-regimen estimand). The percentage was calculated with the use of Rubinâs rules by combining the percentages of patients who met the target in imputed data sets. Panel D shows the percent change (Â±SE) from baseline in lipid levels at 40 weeks, as estimated with the use of log transformation. HDL denotes high-density lipoprotein, LDL low-density lipoprotein, and VLDL very-low-density lipoprotein.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2107519_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2107519/asset/13814f9b-f130-4659-a098-2f008274bdd8/assets/images/large/nejmoa2107519_t1.jpg" height="2628" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>Tirzepatide</span></th><th class="txxx-borders">Semaglutide</th><th class="txxr-borders">Total<br>(N=1878)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">5 mg<br>(N=470)</th><th class="xxxx-borders">10 mg<br>(N=469)</th><th class="xxxx-borders">15 mg<br>(N=470)</th><th class="xxxx-borders">1 mg<br>(N=469)</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Age â yr</td><td class="xxxx-borders shading">56.3Â±10.0</td><td class="xxxx-borders shading">57.2Â±10.5</td><td class="xxxx-borders shading">55.9Â±10.4</td><td class="xxxx-borders shading">56.9Â±10.8</td><td class="xxxr-borders shading">56.6Â±10.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Female sex â no. (%)</td><td class="xxxx-borders">265 (56.4)</td><td class="xxxx-borders">231 (49.3)</td><td class="xxxx-borders">256 (54.5)</td><td class="xxxx-borders">244 (52.0)</td><td class="xxxr-borders">996 (53.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Race or ethnic group â no. (%)<a href="#core-t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">American Indian or Alaska Native</td><td class="xxxx-borders">53 (11.3)</td><td class="xxxx-borders">53 (11.3)</td><td class="xxxx-borders">57 (12.1)</td><td class="xxxx-borders">45 (9.6)</td><td class="xxxr-borders">208 (11.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">6 (1.3)</td><td class="xxxx-borders shading">11 (2.3)</td><td class="xxxx-borders shading">5 (1.1)</td><td class="xxxx-borders shading">3 (0.6)</td><td class="xxxr-borders shading">25 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Black</td><td class="xxxx-borders">28 (6.0)</td><td class="xxxx-borders">21 (4.5)</td><td class="xxxx-borders">15 (3.2)</td><td class="xxxx-borders">15 (3.2)</td><td class="xxxr-borders">79 (4.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">382 (81.3)</td><td class="xxxx-borders shading">376 (80.2)</td><td class="xxxx-borders shading">392 (83.4)</td><td class="xxxx-borders shading">401 (85.5)</td><td class="xxxr-borders shading">1551 (82.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Hispanic</td><td class="xxxx-borders">325 (69.1)</td><td class="xxxx-borders">322 (68.7)</td><td class="xxxx-borders">334 (71.1)</td><td class="xxxx-borders">336 (71.6)</td><td class="xxxr-borders">1317 (70.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Non-Hispanic</td><td class="xxxx-borders shading">145 (30.9)</td><td class="xxxx-borders shading">147 (31.3)</td><td class="xxxx-borders shading">136 (28.9)</td><td class="xxxx-borders shading">133 (28.4)</td><td class="xxxr-borders shading">561 (29.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Glycated hemoglobin level</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Glycated hemoglobin level â %</td><td class="xxxx-borders shading">8.32Â±1.08</td><td class="xxxx-borders shading">8.30Â±1.02</td><td class="xxxx-borders shading">8.26Â±1.00</td><td class="xxxx-borders shading">8.25Â±1.01</td><td class="xxxr-borders shading">8.28Â±1.03</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">â¤8.5% â no. (%)</td><td class="xxxx-borders">293 (62.3)</td><td class="xxxx-borders">294 (62.7)</td><td class="xxxx-borders">303 (64.5)</td><td class="xxxx-borders">302 (64.4)</td><td class="xxxr-borders">1192 (63.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">&gt;8.5% â no. (%)</td><td class="xxxx-borders shading">177 (37.7)</td><td class="xxxx-borders shading">175 (37.3)</td><td class="xxxx-borders shading">167 (35.5)</td><td class="xxxx-borders shading">167 (35.6)</td><td class="xxxr-borders shading">686 (36.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Glycated hemoglobin level â mmol/mol</td><td class="xxxx-borders">67.46Â±11.84</td><td class="xxxx-borders">67.20Â±11.20</td><td class="xxxx-borders">66.78Â±10.97</td><td class="xxxx-borders">66.69Â±10.99</td><td class="xxxr-borders">67.03Â±11.25</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Fasting serum glucose level</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">In mg/dl</td><td class="xxxx-borders">173.8Â±51.87</td><td class="xxxx-borders">174.2Â±49.79</td><td class="xxxx-borders">172.4Â±54.37</td><td class="xxxx-borders">171.4Â±49.77</td><td class="xxxr-borders">172.9Â±51.46</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">In mmol/liter</td><td class="xxxx-borders shading">9.65Â±2.88</td><td class="xxxx-borders shading">9.67Â±2.76</td><td class="xxxx-borders shading">9.57Â±3.02</td><td class="xxxx-borders shading">9.51Â±2.76</td><td class="xxxr-borders shading">9.60Â±2.86</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Duration of diabetes â yr</td><td class="xxxx-borders">9.1Â±7.16</td><td class="xxxx-borders">8.4Â±5.90</td><td class="xxxx-borders">8.7Â±6.85</td><td class="xxxx-borders">8.3Â±5.80</td><td class="xxxr-borders">8.6Â±6.46</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">BMI<a href="#core-t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">33.8Â±6.85</td><td class="xxxx-borders shading">34.3Â±6.60</td><td class="xxxx-borders shading">34.5Â±7.11</td><td class="xxxx-borders shading">34.2Â±7.15</td><td class="xxxr-borders shading">34.2Â±6.93</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Weight â kg</td><td class="xxxx-borders">92.5Â±21.76</td><td class="xxxx-borders">94.8Â±22.71</td><td class="xxxx-borders">93.8Â±21.83</td><td class="xxxx-borders">93.7Â±21.12</td><td class="xxxr-borders">93.7Â±21.86</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Waist circumference â cm</td><td class="xxxx-borders shading">108.06Â±14.81</td><td class="xxxx-borders shading">110.55Â±16.05</td><td class="xxxx-borders shading">109.55Â±15.60</td><td class="xxxx-borders shading">109.04Â±14.90</td><td class="xxxr-borders shading">109.30Â±15.36</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Estimated GFR<a href="#core-t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Mean value â ml/min/1.73 m<sup>2</sup></td><td class="xxxx-borders shading">96.6Â±17.51</td><td class="xxxx-borders shading">95.5Â±16.62</td><td class="xxxx-borders shading">96.3Â±16.92</td><td class="xxxx-borders shading">95.6Â±17.25</td><td class="xxxr-borders shading">96.0Â±17.07</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Value &lt;60 ml/min/1.73 m<sup>2</sup> â no. (%)</td><td class="xxxx-borders">19 (4.0)</td><td class="xxxx-borders">15 (3.2)</td><td class="xxxx-borders">11 (2.3)</td><td class="xxxx-borders">19 (4.1)</td><td class="xxxr-borders">64 (3.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Value â¥60 ml/min/1.73 m<sup>2</sup> â no. (%)</td><td class="xxxx-borders shading">451 (96.0)</td><td class="xxxx-borders shading">454 (96.8)</td><td class="xxxx-borders shading">459 (97.7)</td><td class="xxxx-borders shading">450 (95.9)</td><td class="xxxr-borders shading">1814 (96.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Urinary albumin-to-creatinine ratio â no. (%)<a href="#core-t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">&lt;30</td><td class="xxxx-borders shading">340 (72.3)</td><td class="xxxx-borders shading">353 (75.3)</td><td class="xxxx-borders shading">357 (76.0)</td><td class="xxxx-borders shading">364 (77.6)</td><td class="xxxr-borders shading">1414 (75.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">30 to â¤300</td><td class="xxxx-borders">111 (23.6)</td><td class="xxxx-borders">87 (18.6)</td><td class="xxxx-borders">85 (18.1)</td><td class="xxxx-borders">90 (19.2)</td><td class="xxxr-borders">373 (19.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">&gt;300</td><td class="xxxx-borders shading">18 (3.8)</td><td class="xxxx-borders shading">29 (6.2)</td><td class="xxxx-borders shading">27 (5.7)</td><td class="xxxx-borders shading">15 (3.2)</td><td class="xxxr-borders shading">89 (4.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Use of metformin â no. (%)</td><td class="xxxx-borders">470 (100.0)</td><td class="xxxx-borders">469 (100.0)</td><td class="xxxx-borders">470 (100.0)</td><td class="xxxx-borders">469 (100.0)</td><td class="xxxr-borders">1878 (100.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Blood pressure â mm Hg</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Systolic</td><td class="xxxx-borders">130.53Â±14.11</td><td class="xxxx-borders">131.47Â±13.77</td><td class="xxxx-borders">130.45Â±14.32</td><td class="xxxx-borders">129.96Â±12.99</td><td class="xxxr-borders">130.60Â±13.81</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Diastolic</td><td class="xxxx-borders shading">78.61Â±8.89</td><td class="xxxx-borders shading">80.03Â±9.59</td><td class="xxxx-borders shading">78.97Â±8.97</td><td class="xxxx-borders shading">79.33Â±8.61</td><td class="xxxr-borders shading">79.23Â±9.03</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging03" data-xml-align="left">Pulse rate â bpm</td><td class="xbxx-borders">74.88Â±9.37</td><td class="xbxx-borders">74.55Â±10.75</td><td class="xbxx-borders">74.46Â±9.86</td><td class="xbxx-borders">75.10Â±10.25</td><td class="xbxr-borders">74.75Â±10.07</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plusâminus values are means Â±SD. Patients with a baseline estimated glomerular filtration rate (GFR) of less than 45 ml per minute per 1.73 m<sup>2</sup> were excluded from the trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race or ethnic group was reported by the patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">The mean value of the estimated GFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">For the calculation of the urinary albumin-to-creatinine ratio, the amount of albumin measured in milligrams per deciliter was divided by the amount of creatinine measured in grams per deciliter.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline in the Modified Intention-to-Treat Population.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2107519_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2107519_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2107519/asset/10621e72-34da-439d-8636-52196bc57669/assets/images/large/nejmoa2107519_t2.jpg" height="2908" width="2617" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="6"><span>Tirzepatide</span></th><th class="txxx-borders" colspan="2"><span>Semaglutide</span></th><th class="txxr-borders" colspan="2"><span>Total<br>(N=1878)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>5 mg<br>(N=470)</span></th><th class="xxxx-borders" colspan="2"><span>10 mg<br>(N=469)</span></th><th class="xxxx-borders" colspan="2"><span>15 mg<br>(N=470)</span></th><th class="xxxx-borders" colspan="2"><span>1 mg<br>(N=469)</span></th><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">No. of <br>patients (%)</th><th class="xxxx-borders">No. of<br> events</th><th class="xxxx-borders">No. of<br> patients (%)</th><th class="xxxx-borders">No. of<br> events</th><th class="xxxx-borders">No. of<br> patients (%)</th><th class="xxxx-borders">No. of<br> events</th><th class="xxxx-borders">No. of <br>patients (%)</th><th class="xxxx-borders">No. of <br>events</th><th class="xxxx-borders">No. of <br>patients (%)</th><th class="xxxr-borders">No. of<br> events</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Patients with â¥1 adverse event</td><td class="xxxx-borders shading">299 (63.6)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">322 (68.7)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">324 (68.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">301 (64.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1246 (66.3)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders" data-xml-align="left">Patients with â¥1 serious adverse event</td><td class="xxxx-borders">33 (7.0)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">25 (5.3)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">27 (5.7)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">13 (2.8)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">98 (5.2)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">Death<a href="#core-t2fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">13 (0.7)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse events leading to discontinuation of tirzepatide or semaglutide</td><td class="xxxx-borders">28 (6.0)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">40 (8.5)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">40 (8.5)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">19 (4.1)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">127 (6.8)</td><td class="xxxr-borders">â</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Adverse events occurring in â¥0.2% of the overall population (i.e., 3 patients) and leading to discontinuation of tirzepatide or semaglutide</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">6 (1.3)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">7 (1.5)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">4 (0.9)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">4 (0.9)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">21 (1.1)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Vomiting</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">3 (0.6)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">12 (0.6)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">3 (0.6)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">6 (1.3)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">11 (0.6)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">9 (0.5)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Dyspepsia</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">0</td><td class="xxxx-borders">â</td><td class="xxxx-borders">5 (0.3)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">5 (0.3)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Fatigue</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">4 (0.2)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Elevated blood calcitonin level</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">3 (0.2)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Constipation</td><td class="xxxx-borders">0</td><td class="xxxx-borders">â</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">0</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">3 (0.2)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Covid-19ârelated pneumonia</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">3 (0.2)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Injection-site reaction</td><td class="xxxx-borders">0</td><td class="xxxx-borders">â</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">0</td><td class="xxxx-borders">â</td><td class="xxxx-borders">3 (0.2)</td><td class="xxxr-borders">â</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Adverse events occurring in â¥5% of patients in any treatment group, according to preferred term</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">82 (17.4)</td><td class="xxxx-borders">111</td><td class="xxxx-borders">90 (19.2)</td><td class="xxxx-borders">124</td><td class="xxxx-borders">104 (22.1)</td><td class="xxxx-borders">136</td><td class="xxxx-borders">84 (17.9)</td><td class="xxxx-borders">126</td><td class="xxxx-borders">360 (19.2)</td><td class="xxxr-borders">497</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">62 (13.2)</td><td class="xxxx-borders shading">120</td><td class="xxxx-borders shading">77 (16.4)</td><td class="xxxx-borders shading">99</td><td class="xxxx-borders shading">65 (13.8)</td><td class="xxxx-borders shading">102</td><td class="xxxx-borders shading">54 (11.5)</td><td class="xxxx-borders shading">68</td><td class="xxxx-borders shading">258 (13.7)</td><td class="xxxr-borders shading">389</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xxxx-borders">27 (5.7)</td><td class="xxxx-borders">35</td><td class="xxxx-borders">40 (8.5)</td><td class="xxxx-borders">56</td><td class="xxxx-borders">46 (9.8)</td><td class="xxxx-borders">61</td><td class="xxxx-borders">39 (8.3)</td><td class="xxxx-borders">53</td><td class="xxxx-borders">152 (8.1)</td><td class="xxxr-borders">205</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Dyspepsia</td><td class="xxxx-borders shading">34 (7.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">29 (6.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">43 (9.1)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">31 (6.6)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">137 (7.3)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders">35 (7.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">34 (7.2)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">42 (8.9)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">25 (5.3)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">136 (7.2)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">32 (6.8)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">21 (4.5)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">21 (4.5)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">27 (5.8)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">101 (5.4)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders">14 (3.0)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">21 (4.5)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">24 (5.1)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">24 (5.1)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">83 (4.4)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders shading" data-xml-align="left">All gastrointestinal adverse events</td><td class="xxxx-borders shading">188 (40.0)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">216 (46.1)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">211 (44.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">193 (41.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">808 (43.0)</td><td class="xxxr-borders shading">â</td></tr><tr data-type="row"><td class="xxlx-borders">Other adverse events</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hypoglycemia, blood glucose level &lt;54 mg/dl</td><td class="xxxx-borders shading">3 (0.6)</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">8 (1.7)</td><td class="xxxx-borders shading">10</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">14 (0.7)</td><td class="xxxr-borders shading">17</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Severe hypoglycemia</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.2)<a href="#core-t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">1<a href="#core-t2fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (0.1)</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Injection-site reaction</td><td class="xxxx-borders shading">9 (1.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">13 (2.8)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">21 (4.5)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">44 (2.3)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjudicated pancreatitis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">â</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">3 (0.6)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">7 (0.4)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Cholelithiasis</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">â</td><td class="xxxx-borders shading">14 (0.7)</td><td class="xxxr-borders shading">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hypersensitivity<a href="#core-t2fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">9 (1.9)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">13 (2.8)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">8 (1.7)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">11 (2.3)</td><td class="xxxx-borders">â</td><td class="xxxx-borders">41 (2.2)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Diabetic retinopathy<a href="#core-t2fn5" role="doc-noteref">Â¶</a></td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">â</td><td class="xbxx-borders shading">2 (0.4)</td><td class="xbxx-borders shading">â</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">â</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">â</td><td class="xbxx-borders shading">2 (0.1)</td><td class="xbxr-borders shading">â</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Patients may be counted in more than one category. The number of events was reported if available. To convert blood glucose values to millimoles per liter, multiply by 0.05551.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Deaths are also included as serious adverse events and discontinuations due to adverse events. No deaths were considered by the investigators to be related to tirzepatide or semaglutide. All deaths were adjudicated by an external committee of physicians with cardiology expertise.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">This patient had a hypoglycemic event that was not considered by the investigator to be severe, but it was reported as a serious adverse event.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">This category includes immediate (&lt;24 hours after trial drug administration) and nonimmediate (&gt;24 hours after trial drug administration) hypersensitivity events. One immediate event was reported in the tirzepatide 15-mg group.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">Diabetic retinopathy was confirmed by funduscopic examination.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events and Safety.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2107519_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2107519</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">American Diabetes Association. Introduction: standards of medical care in diabetes â 2021. <em>Diabetes Care</em> 2021;44:Suppl 1:S1-S2.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc21-Sint" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33298409/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000609468800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Introduction%3A+standards+of+medical+care+in+diabetes+%E2%80%94+2021.&amp;publication_year=2021&amp;journal=Diabetes+Care&amp;pages=S1-S2&amp;doi=10.2337%2Fdc21-Sint&amp;pmid=33298409" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <em>Diabetologia</em> 2020;63:221-228.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00125-019-05039-w" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31853556/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000511867900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2019+update+to%3A+Management+of+hyperglycaemia+in+type+2+diabetes%2C+2018%3A+a+consensus+report+by+the+American+Diabetes+Association+%28ADA%29+and+the+European+Association+for+the+Study+of+Diabetes+%28EASD%29.&amp;publication_year=2020&amp;journal=Diabetologia&amp;pages=221-228&amp;doi=10.1007%2Fs00125-019-05039-w&amp;pmid=31853556" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">MÃ¼ller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). <em>Mol Metab</em> 2019;30:72-130.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.molmet.2019.09.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31767182/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000500474800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glucagon-like+peptide+1+%28GLP-1%29.&amp;publication_year=2019&amp;journal=Mol+Metab&amp;pages=72-130&amp;doi=10.1016%2Fj.molmet.2019.09.010&amp;pmid=31767182" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Christensen M, Vedtofte L, Holst JJ, VilsbÃ¸ll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. <em>Diabetes</em> 2011;60:3103-3109.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/db11-0979" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21984584/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297715100003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glucose-dependent+insulinotropic+polypeptide%3A+a+bifunctional+glucose-dependent+regulator+of+glucagon+and+insulin+secretion+in+humans.&amp;publication_year=2011&amp;journal=Diabetes&amp;pages=3103-3109&amp;doi=10.2337%2Fdb11-0979&amp;pmid=21984584" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Yip RG, Boylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocytes. <em>Endocrinology</em> 1998;139:4004-4007.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1210/endo.139.9.6288" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9724057/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000075500500042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Functional+GIP+receptors+are+present+on+adipocytes.&amp;publication_year=1998&amp;journal=Endocrinology&amp;pages=4004-4007&amp;doi=10.1210%2Fendo.139.9.6288&amp;pmid=9724057" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? <em>Trends Endocrinol Metab</em> 2020;31:410-421.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.tem.2020.02.006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32396843/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000532680200005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=How+may+GIP+enhance+the+therapeutic+efficacy+of+GLP-1%3F&amp;publication_year=2020&amp;journal=Trends+Endocrinol+Metab&amp;pages=410-421&amp;doi=10.1016%2Fj.tem.2020.02.006&amp;pmid=32396843" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] which may prevent ectopic fat deposition. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] a GLP-1âinduced reduction in food intake. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. <em>Mol Metab</em> 2018;18:3-14.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.molmet.2018.09.009" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30473097/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450929200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=LY3298176%2C+a+novel+dual+GIP+and+GLP-1+receptor+agonist+for+the+treatment+of+type+2+diabetes+mellitus%3A+from+discovery+to+clinical+proof+of+concept.&amp;publication_year=2018&amp;journal=Mol+Metab&amp;pages=3-14&amp;doi=10.1016%2Fj.molmet.2018.09.009&amp;pmid=30473097" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a GLP-1âinduced reduction in food intake. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and includes a C20 fatty diacid moiety. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] once-weekly subcutaneous administration. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. <em>Cell Metab</em> 2021;33(4):833.e5-844.e5.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cmet.2021.01.015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33571454/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000637370500017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+glucose-dependent+insulinotropic+polypeptide+%28GIP%29+regulates+body+weight+and+food+intake+via+CNS-GIPR+signaling.&amp;publication_year=2021&amp;journal=Cell+Metab&amp;pages=833.e5-844.e5&amp;doi=10.1016%2Fj.cmet.2021.01.015&amp;pmid=33571454" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. <em>Lancet</em> 2018;392:2180-2193.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)32260-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30293770/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450358900030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+LY3298176%2C+a+novel+dual+GIP+and+GLP-1+receptor+agonist%2C+in+patients+with+type+2+diabetes%3A+a+randomised%2C+placebo-controlled+and+active+comparator-controlled+phase+2+trial.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=2180-2193&amp;doi=10.1016%2FS0140-6736%2818%2932260-8&amp;pmid=30293770" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] hemoglobin level and weight at 26 weeks. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] which involved more rapid escalation. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">AhrÃ©n B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. <em>Lancet Diabetes Endocrinol</em> 2017;5:341-354.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(17)30092-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28385659/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once-weekly+semaglutide+versus+once-daily+sitagliptin+as+an+add-on+to+metformin%2C+thiazolidinediones%2C+or+both%2C+in+patients+with+type+2+diabetes+%28SUSTAIN+2%29%3A+a+56-week%2C+double-blind%2C+phase+3a%2C+randomised+trial.&amp;publication_year=2017&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=341-354&amp;doi=10.1016%2FS2213-8587%2817%2930092-X&amp;pmid=28385659" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. <em>Lancet Diabetes Endocrinol</em> 2018;6:275-286.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(18)30024-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29397376/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Semaglutide+versus+dulaglutide+once+weekly+in+patients+with+type+2+diabetes+%28SUSTAIN+7%29%3A+a+randomised%2C+open-label%2C+phase+3b+trial.&amp;publication_year=2018&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=275-286&amp;doi=10.1016%2FS2213-8587%2818%2930024-X&amp;pmid=29397376" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Sorli C, Harashima S-I, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. <em>Lancet Diabetes Endocrinol</em> 2017;5:251-260.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(17)30013-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28110911/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once-weekly+semaglutide+monotherapy+versus+placebo+in+patients+with+type+2+diabetes+%28SUSTAIN+1%29%3A+a+double-blind%2C+randomised%2C+placebo-controlled%2C+parallel-group%2C+multinational%2C+multicentre+phase+3a+trial.&amp;publication_year=2017&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=251-260&amp;doi=10.1016%2FS2213-8587%2817%2930013-X&amp;pmid=28110911" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. <em>Lancet Diabetes Endocrinol</em> 2019;7:356-367.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(19)30066-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30833170/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Semaglutide+once+weekly+as+add-on+to+SGLT-2+inhibitor+therapy+in+type+2+diabetes+%28SUSTAIN+9%29%3A+a+randomised%2C+placebo-controlled+trial.&amp;publication_year=2019&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=356-367&amp;doi=10.1016%2FS2213-8587%2819%2930066-X&amp;pmid=30833170" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. <em>Diabetes Care</em> 2018;41:258-266.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc17-0417" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29246950/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430455100015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once-weekly+semaglutide+versus+exenatide+ER+in+subjects+with+type+2+diabetes+%28SUSTAIN+3%29%3A+a+56-week%2C+open-label%2C+randomized+clinical+trial.&amp;publication_year=2018&amp;journal=Diabetes+Care&amp;pages=258-266&amp;doi=10.2337%2Fdc17-0417&amp;pmid=29246950" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. <em>Lancet Diabetes Endocrinol</em> 2017;5:355-366.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(17)30085-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28344112/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once-weekly+semaglutide+versus+once-daily+insulin+glargine+as+add-on+to+metformin+%28with+or+without+sulfonylureas%29+in+insulin-naive+patients+with+type+2+diabetes+%28SUSTAIN+4%29%3A+a+randomised%2C+open-label%2C+parallel-group%2C+multicentre%2C+multinational%2C+phase+3a+trial.&amp;publication_year=2017&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=355-366&amp;doi=10.1016%2FS2213-8587%2817%2930085-2&amp;pmid=28344112" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. <em>J Clin Endocrinol Metab</em> 2018;103:2291-2301.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1210/jc.2018-00070" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29688502/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000434881400026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Semaglutide+added+to+basal+insulin+in+type+2+diabetes+%28SUSTAIN+5%29%3A+a+randomized%2C+controlled+trial.&amp;publication_year=2018&amp;journal=J+Clin+Endocrinol+Metab&amp;pages=2291-2301&amp;doi=10.1210%2Fjc.2018-00070&amp;pmid=29688502" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Lingvay I, Catarig A-M, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. <em>Lancet Diabetes Endocrinol</em> 2019;7:834-844.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(19)30311-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31540867/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once-weekly+semaglutide+versus+daily+canagliflozin+as+add-on+to+metformin+in+patients+with+type+2+diabetes+%28SUSTAIN+8%29%3A+a+double-blind%2C+phase+3b%2C+randomised+controlled+trial.&amp;publication_year=2019&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=834-844&amp;doi=10.1016%2FS2213-8587%2819%2930311-0&amp;pmid=31540867" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. <em>N Engl J Med</em> 2016;375:1834-1844.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_19_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2107519&amp;key=10.1056%2FNEJMoa1607141&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27633186/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387534200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Semaglutide+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=1834-1844&amp;doi=10.1056%2FNEJMoa1607141&amp;pmid=27633186" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Capehorn MS, Catarig A-M, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). <em>Diabetes Metab</em> 2020;46:100-109.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.diabet.2019.101117" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31539622/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000528270300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+once-weekly+semaglutide+1.0+mg+vs+once-daily+liraglutide+1.2+mg+as+add-on+to+1-3+oral+antidiabetic+drugs+in+subjects+with+type+2+diabetes+%28SUSTAIN+10%29.&amp;publication_year=2020&amp;journal=Diabetes+Metab&amp;pages=100-109&amp;doi=10.1016%2Fj.diabet.2019.101117&amp;pmid=31539622" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been reported to be as high as 6.5 kg. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of Type 2 Diabetes) clinical trial program. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Ozempic: USPI product information. Bagsvaerd, Denmark: Novo Nordisk, 2021 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ozempic%3A+USPI+product+information&amp;publication_year=2021" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Davies MJ, DâAlessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <em>Diabetes Care</em> 2018;41:2669-2701.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci18-0033" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30291106/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450560000037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Management+of+hyperglycemia+in+type+2+diabetes%2C+2018%3A+a+consensus+report+by+the+American+Diabetes+Association+%28ADA%29+and+the+European+Association+for+the+Study+of+Diabetes+%28EASD%29.&amp;publication_year=2018&amp;journal=Diabetes+Care&amp;pages=2669-2701&amp;doi=10.2337%2Fdci18-0033&amp;pmid=30291106" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Meier JJ, Nauck MA. Incretin-based therapies: where will we be 50 years from now? <em>Diabetologia</em> 2015;58:1745-1750.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00125-015-3608-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25994073/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000358877300013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Incretin-based+therapies%3A+where+will+we+be+50+years+from+now%3F&amp;publication_year=2015&amp;journal=Diabetologia&amp;pages=1745-1750&amp;doi=10.1007%2Fs00125-015-3608-6&amp;pmid=25994073" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. <em>Diabetes Obes Metab</em> 2020;22:938-946.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/dom.13979" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31984598/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000512459700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+tolerability+of+tirzepatide%2C+a+dual+glucose-dependent+insulinotropic+peptide+and+glucagon-like+peptide-1+receptor+agonist+in+patients+with+type+2+diabetes%3A+a+12-week%2C+randomized%2C+double-blind%2C+placebo-controlled+study+to+evaluate+different+dose-escalation+regimens.&amp;publication_year=2020&amp;journal=Diabetes+Obes+Metab&amp;pages=938-946&amp;doi=10.1111%2Fdom.13979&amp;pmid=31984598" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Davies M, FÃ¦rch L, Jeppesen OK, et al. Semaglutide 2Â·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. <em>Lancet</em> 2021;397:971-984.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)00213-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33667417/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000627814200026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Semaglutide+2%C2%B74+mg+once+a+week+in+adults+with+overweight+or+obesity%2C+and+type+2+diabetes+%28STEP+2%29%3A+a+randomised%2C+double-blind%2C+double-dummy%2C+placebo-controlled%2C+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=971-984&amp;doi=10.1016%2FS0140-6736%2821%2900213-0&amp;pmid=33667417" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 25, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2109957" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Breaking New Ground with Incretin Therapy in Diabetes</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">K.R. Tuttle</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Feb 16, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2114590" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Peabody, Massachusetts</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879655/adult-primary-care-physician-internal-medicine-family-medicine-peabody-lynnfield/?query=fjwp&amp;rid=980">Adult Primary Care Physician - Internal Medicine/Family Medicine - Peabody-Lynnfield</a></div></div><div class="nejm-widget_item"><div><span> Port Jefferson, New York</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/697837/director-of-gynecology-mather-hospital-northwell-health-50k-sign-on-bonus-/?query=fjwp&amp;rid=3059">Director of Gynecology, Mather Hospital, Northwell Health **50K Sign-on bonus!**</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/893374/radiologist-opening-30-minutes-from-boston-ma-sign-on-bonus/?query=fjwf&amp;rid=475926">Radiologist Opening 30 Minutes from Boston, MA - Sign-On Bonus</a></div></div><div class="nejm-widget_item"><div><span>United Arab Emirates</span></div><div><span>ENT / Head &amp; Neck Surgery</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885171/staff-physician-ent-otolaryngology-for-cleveland-clinic-abudhabi/?query=fjwf&amp;rid=2201">Staff Physician, ENT/Otolaryngology For Cleveland Clinic AbuDhabi</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886947/radiology-position-in-southeastern-ma-2-year-partnership-track/?query=fjwf&amp;rid=475926">Radiology Position in Southeastern MA | 2-Year Partnership Track</a></div></div><div class="nejm-widget_item"><div><span> Akron, Ohio</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/878642/internal-medicine-akron-general/?query=fjwf&amp;rid=2201">Internal Medicine- Akron General</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2107519&amp;pubId=41290649&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d691a370eaf256-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d691a370eaf256-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d691a370eaf256-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$474675997$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$474675997$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$474675997$--></div></div><div class="mlt-body"><!--?lit$474675997$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$474675997$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$474675997$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$474675997$-->May 11, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2416394?query=recirc_Semantic" target="_self">Tirzepatide as Compared with Semaglutide for the Treatment of Obesity</a></div><div class="mlt-article-authors"><!--?lit$474675997$-->L.J. Aronne and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$474675997$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$474675997$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$474675997$-->Oct 31, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2409972?query=recirc_Semantic" target="_self">Glucagon-Like Peptide-1 Receptor Agonists and Osteoarthritis</a></div><div class="mlt-article-authors"><!--?lit$474675997$-->D.T. Felson</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$474675997$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$474675997$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$474675997$-->Mar 06, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2410819?query=recirc_Semantic" target="_self">Tirzepatide for Obesity Treatment and Diabetes Prevention</a></div><div class="mlt-article-authors"><!--?lit$474675997$-->A.M. Jastreboff and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$474675997$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$474675997$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$474675997$-->Jan 30, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2410027?query=recirc_Semantic" target="_self">Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity</a></div><div class="mlt-article-authors"><!--?lit$474675997$-->M. Packer and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$474675997$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$474675997$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$474675997$-->Jul 25, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2401943?query=recirc_Semantic" target="_self">Tirzepatide for Metabolic DysfunctionâAssociated Steatohepatitis with Liver Fibrosis</a></div><div class="mlt-article-authors"><!--?lit$474675997$-->R. Loomba and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2107519?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2107519" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2107519.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2107519"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2107454" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2026845" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f0.jpg"><img src="/cms/10.1056/NEJMoa2107519/asset/3224f90f-0e67-4064-b4c3-5a2a1ba8a7b4/assets/images/large/nejmoa2107519_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f1.jpg"><img src="/cms/10.1056/NEJMoa2107519/asset/cb8606e2-07b4-4eb5-8a7f-c9349641ebd8/assets/images/large/nejmoa2107519_f1.jpg" height="2442" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Effect of Once-Weekly Tirzepatide, as Compared with Semaglutide, on the Glycated Hemoglobin Level, Percentage of Patients Who Met Glycated Hemoglobin Level Targets, and Fasting Serum Glucose Levels.</div><div class="notes"><div role="doc-footnote">Least-squares means (Â±SE) are presented, unless otherwise noted. Error bars indicate the standard error. Estimated treatment differences (ETDs) are least-squares means (95% confidence interval) at 40 weeks in the modified intention-to-treat population. Panel A shows the change from baseline in the glycated hemoglobin level at 40 weeks, as assessed with the use of analysis of covariance with multiple imputation according to treatment for the missing glycated hemoglobin level at 40 weeks (treatment-regimen estimand). Panel B shows the values for glycated hemoglobin levels over time, derived from a mixed-model repeated-measures analysis (efficacy estimand). Arrows indicate the times at which the maintenance doses of tirzepatide (5 mg, 10 mg, or 15 mg) and semaglutide 1 mg were achieved. Panel C shows the percentage of patients who met glycated hemoglobin level targets of less than 7.0%, 6.5% or less, and less than 5.7% at 40 weeks (treatment-regimen estimand). The percentage was calculated with the use of Rubinâs rules by combining the percentages of patients who met the target in imputed data sets. The glycated hemoglobin levels of 6.5% or less and less than 5.7% (tirzepatide 5-mg group only) were not controlled for type 1 errors; thus, P values are not presented. Panel D shows fasting serum glucose values over time, derived from mixed-model repeated-measures analysis (efficacy estimand). Arrows indicate the times at which the maintenance doses of tirzepatide (5 mg, 10 mg, or 15 mg) and semaglutide 1 mg were achieved.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2107519_f2.jpg"><img src="/cms/10.1056/NEJMoa2107519/asset/aef32ee9-ba38-45e0-86dc-a9d7ac0164fc/assets/images/large/nejmoa2107519_f2.jpg" height="2281" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Effect of Once-Weekly Tirzepatide, as Compared with Semaglutide, on Body Weight, the Percentage of Patients Who Met Weight-Loss Goals, and the Lipid Profile.</div><div class="notes"><div role="doc-footnote">Least-squares means (Â±SE) are presented, unless otherwise noted. Error bars indicate the standard error. Panel A shows the change from baseline in body weight at 40 weeks, as assessed with analysis of covariance with multiple imputation for treatment for missing weight at 40 weeks (treatment-regimen estimand). ETDs are least-squares means (95% confidence interval) at 40 weeks in the modified intention-to-treat population. Panel B shows the change from baseline in body weight over time, derived from a mixed-model repeated-measures analysis (efficacy estimand). The percent changes from baseline values at 40 weeks are shown in parentheses. Arrows indicate the times at which the maintenance doses of tirzepatide (5 mg, 10 mg, or 15 mg) and semaglutide 1 mg were achieved. Panel C shows the percentage of patients who had body-weight reductions of at least 5%, 10%, or 15% from baseline to week 40 (treatment-regimen estimand). The percentage was calculated with the use of Rubinâs rules by combining the percentages of patients who met the target in imputed data sets. Panel D shows the percent change (Â±SE) from baseline in lipid levels at 40 weeks, as estimated with the use of log transformation. HDL denotes high-density lipoprotein, LDL low-density lipoprotein, and VLDL very-low-density lipoprotein.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline in the Modified Intention-to-Treat Population.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events and Safety.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/385/6" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 385 No. 6</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 05, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2107454" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.D. Gillmore and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 05, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2100990" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Decompression with or without Fusion in Degenerative Lumbar Spondylolisthesis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">I.M. Austevoll and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 05, 2021</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2026845" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R. Mathew and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2107519%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2107519&amp;pubId=41290649&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2107519%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2107519&amp;pubId=41290649&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright Â© 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id07856250559928328" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d691a370eaf256-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d691a370eaf256-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d691a370eaf256-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d691a370eaf256-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d691a370eaf256-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d691a370eaf256-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d691a370eaf256-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d691a370eaf256-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d691a370eaf256-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d691a370eaf256-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d691a36d71f256',t:'MTc0OTUzNDM5My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d691a36d71f256&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">â</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">Moreâ¦</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><tcl-wjffvkcdnpyz></tcl-wjffvkcdnpyz><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2107519?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-transactionid="3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" id="captureIFrame_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" target="captureIFrame_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="â" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" name="capture_screen"><input id="capture_signIn_js_version_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" name="js_version"><input id="capture_signIn_transactionId_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-capturefield="undefined" value="3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" type="hidden" class="capture_transactionId_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" name="capture_transactionId"><input id="capture_signIn_form_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" name="form"><input id="capture_signIn_flow_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" name="flow"><input id="capture_signIn_client_id_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" name="client_id"><input id="capture_signIn_redirect_uri_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" name="redirect_uri"><input id="capture_signIn_response_type_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" name="response_type"><input id="capture_signIn_flow_version_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" name="flow_version"><input id="capture_signIn_settings_version_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" name="settings_version"><input id="capture_signIn_locale_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" name="locale"><input id="capture_signIn_recaptcha_version_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_3i23bh7q37ujj972tnfcgpdti3fujowjcsvtmnv0" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>